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INTRODUCTION
A Symposium on Diabetes was presi;:nted at the
Medical College of Virginia on September 23, 1976,
sponsored jointly by the Division of Endocrinology
and Metabolism of the Department of Medicine, and
by the Department of Continuing Education. The
symposium was also sponsored in part by a grantin-aid for continuing medical education from the
Upjohn Company .
The morning portion of the program presented
summaries of some of the current important research
in the field of diabetes, while the afternoon program
was devoted to practical aspects of the treatment of
diabetic patients. The emphasis was on the importance of achieving as good chemical control as possible, although some of the practical difficulties in
accompanying such control are explained. We are
grateful to the members of the MCV faculty and
the guest faculty who presented these papers, and
to our co-sponsors who made this program possible.
H . ST. GEORGE TUCKER, M .D.

Professor
Department of Endocrinology and Metabolism

Somatostatin: Diverse Physiological Roles
and Therapeutic Implications*
GORDON C. WEIR, M .D .

Associate Professor of Medicine , Division of Endocrinology, Medical College of Virginia, Health Sciences
Division of Virginia Commonwealth University, Richmond, Virginia

S. BONNER WEIR , PH.D

Research Associate, Division of Endocrinology, Medical College of Virginia, Health Sciences Division of Virginia
Commonwealth University, Richmond, Virginia

In its brief lifetime as a known peptide, somatostatin has provided a truly remarkable story filled
with surprising developments from unexpected quarters. The foundation was set in 1969, when Krulich
and McCann 1 reported that fractions of a crude hypothalamic extract inhibited the secretion of growth
hormone . In 1973, Guillemin's laboratory reported
the sequence and synthesis of a fourteen amino acid
peptide with the same inhibitory effect. 2·3 It occurs in
both a cyclic and linear form, each displaying equal
biological activity. Somatostatin was assigned as its
name, but it is also commonly referred to as growth
hormone release inhibitory factor (G H RI F) or somatotropin-release inhibiting factor (SRIF).
Characterization of somatostatin's biological activity proceeded rapidly once the synthetic peptide
became available. It proved to be a potent inhibitor
of thyroid stimulating hormone (TSH). 4 No effect
was found upon prolactin or adrenocorticotropic
hormone (ACTH) secretion except in the pathological situations of acromegaly 5 and Nelson's syndrome,6 where inhibition has been described. The
secretion of follicle-stimulating hormone (FSH) and
*This paper is published with permission of Hospital Formulary. Correspondence and reprint requests to Dr. Gordon C. Weir,
Bo x 775, Medical College of Virginia, Richmond , Virginia 23298.
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luteinizing hormone (LH) is not inhibited by somatostatin.7 There was great surprise when investigators
in Seattle, working with baboons, found that somatostatin inhibited the secretion of two pancreatic hormones, insulin and glucagon, 8 and, as studies expanded to other organs, the inhibition of gastrin, 9
secret in , 10 gastric acid and pepsin secretion, 9 and secretin-stimulated exocrine pancreatic secretion 10 were
described. Very little is known about the molecular
mechanisms of somatostatin effects, but clues are
being provided by the findings that inhibition of insulin secretion can be partially reversed by high calcium concentration 11 and by alpha adrenergic blockade with phentolamine. 12 Furthermore, somatostatin
appears to interfere with calcium uptake by islets 13
and may inhibit tissue cyclic adenosine monophosphate (AMP) accumulation. 14 Both events are
thought to be important in the secretory process.
Diabetes researchers became interested when it
was shown that somatostatin infusions caused a fall
of blood glucose in both normal subjects and diabetics .15 In addition, somatostatin markedly slowed the
development of ketoacidosis in insulin-deprived juvenile-type diabetics, 16 even though it did little to reverse established ketoacidosis. 17 Until then there was
no convincing evidence that glucagon was anything
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more than a vestigial hormone, only continual debates about the theoretical relative contributions of
insulin and glucagon to metabolic processes.
The widespread effects of insulin upon hepatic
and peripheral tissues are well known, but glucagon's
effects appear to be more limited. Although pharmacological amounts of glucagon can influence many
organs, physiological concentrations act primarily on
the liver, and probably have minor lipolytic effects on
adipose tissue. Hepatic glycogenolysis and gluconeogenesis can both be stimulated by glucagon, thus
leading to enhanced hepatic glucose output. It is also
now clear that glucagon has a direct stimulatory effect upon hepatic ketogenesis. 18 The issue, however, is
whether these effects are trivial and easily nullified by
small amounts of insulin or whether they are physiologically important. Somatostatin has become a
useful pharmacological tool to help answer these
questions, because in addition to being able to block
insulin and glucagon secretion, it has no known direct effect upon hepatic glucose output or peripheral
glucose utilization. Several laboratories have now
shown that the fall of blood glucose during a somatostatin infusion is secondary to a reduction of hepatic glucose output. The interpretation has therefore
been made that inhibition of glucagon in these shortterm experiments was more important than the inhibition of insulin . A similar fall in glucose was found
in a diabetic with hypophysectomy, indicating that
growth hormone inhibition did not have much influence.15
These unexpected findings made it difficult to
understand why patients with pancreatectomies were
hyperglycemic. According to the results of the somatostatin experiments, the removal of both insulin and
glucagon surgically should have led to hypoglycemia.
One finding used to reconcile this puzzle was that
insulin-deprived pancreatectomized dogs have abundant amounts of extra-pancreatic glucagon which is
known to be primarily of gastric origin. 19 Humans,
however, appear to have very little gastric glucagon. 20
The best explanation for the paradox appears to be
that glucagon's effects are only transient; thus, a
glucagon infusion leads to an increase of hepatic
glucose output which lasts for about an hour. 21 Similarly, if glucagon is "removed" with somatostatin,
there is a transient reduction in hepatic glucose output.22 Therefore, during chronic somatostatin infusions, a fall of blood glucose is seen before hyperglycemia, which appears as insulin deficiency
dominates.22 These experiments and others have led
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some to say that glucagon's influence on blood glucose homeostasis is minor and that the hyperglycemia
of diabetes is almost entirely secondary to insulin
deficiency. The acceptance of a dominant role for
insulin seems inescapable, but glucagon may still
have important effects. Daily physiological events
bear little relation to infusions of glucagon or somatostatin; glucagon concentrations do not remain constant during the day but fluctuate considerably, particularly with meals. Thus, if each one of these
fluctuations led to a transient effect on blood glucose
lasting for even 45 mintues, it is clear that glucagon 's
overall influence throughout the day could be substantial. Furthermore, there is abundant evidence
that glucagon secretion is increased in diabetes.23 To
answer some of these critical questions, workers have
given glucagon infusions and injections, trying to stay
within the concentrations thought to be physiologicaJ.2•- 25 There is agreement that glucagon has
hyperglycemic effects when unopposed by insulin but
disagreement that it causes deterioration of control
during insulin therapy in diabetics. In addition, there .
is growing acceptance that endogenous insulin secretion in normal subjects can effectively counter the
effects of artificially-raised plasma glucagon concentrations. Therefore, despite large amounts of recent
work, there remains much disagreement about glucagon's importance in diabetes.
This rather elaborate background is necessary to
understand somatostatin's possible usefulness as a
therapeutic agent. Its ability to lower blood glucose is
presumed to be mediated primarily via glucagon inhibition. Therefore the question of glucagon's contribution to the hyperglycemia of diabetes is of utmost
importance. During debates about somatostatin's potential in diabetes a commonly raised question is,
"Why worry about somatostatin? Why not give more
insulin?" Somatostatin 's advocates argue that following each meal there is a glucagon rise which drives
blood glucose to unacceptable postprandial peaks
even in so-called well-controlled diabetics. Aborting
these glucagon rises with somatostatin would therefore minimize glucose excursions in a way unachievable with conventional insulin therapy. New data
adding more confusion to these concepts is the finding that somatostatin can impair carbohydrate absorption by the gastrointestinal tract and may lower
postprandial glucose by a mechanism independent of
glucagon. 27
As indicated above, much of the controversy
about somatostatin centers on its possible effects
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upon glucose control irt di a betes. Even though data
showing a connection between blood glucose and
complications is not conclusive, there is enough circumstantial evidence to warrant the pursuit of optimal control. Another factor linked to complications
is growth hormone. Even though large, well-controlled studies are still not available, the weight of
evidence suggests that pituitary ablation has a beneficial effect upon diabetic retinopathy. Possibly important as well is the observation that plasma growth
hormone levels are increased in diabetics , when control is poor 28 or during exercise. 29 ·30 Somatostatin
therefore may possibly benefit diabetics through two
mechanisms-control of blood glucose and suppression of growth hormone secretion.
Obviously much more work is needed before
somatostatin's ultimate value as a therapeutic tool
can be assessed and there are many hurdles which
need to be overcome. Long-acting preparations must
be developed , as injections before each meal are obviously impractical. A protamine-zinc somatostatin
preparation has been found to increase the duration
of action in rats 31 but has been unsuccessful in primates . There were early fears that inhibitory effects
upon platelet function would lead to serious bleeding
problems, but recent thorough studies have dispelled
some of these anxieties. 32 Even though chronic suppression of growth hormone might help some diabetics, growth retardation in children would not be acceptable. Furthermore, it is possible that
somatostatin's effecis on the gastrointestinal tract
will produce discomfort and maldigestion leading to
nutritional deficiency. Efforts are underway to develop somatostatin analogues which will selectively
suppress glucagon secretion and, although selectivity
has not yet been accomplished, a D-tryptophan 8somatostatin analogue has been synthesized which is
eight times more potent than somatostatin in inhibiting growth hormone, insulin, and glucagon secretion.33 In addition to its potential usefulness in diabetes, somatostatin may be of some benefit in the
treatment of acromegaly, 5 peptic ulcer disease, and
metastatic insulinomas and glucogonomas.
Another area of research has focused upon the
localization of somatostatin. lmmunohistochemical
techniques, in particular immunofluorescence, have
been very useful for accurate localization, and radioimmunoassay has permitted quantitation of somatostatin immunoreactivity. The major obstacle in the
development of radioimmunoassays was the problem
of labeling somatostatin. Labeling with 1251 of the
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tyrosine of the synthetic analogue 1-tyrosinated somatostatin provided the breakthrough and several very
specific, highly sensitive assay systems have become
available through the research of Arimura et al 34 and
by Y.C. Patel, MD and S. Reichlin, MD (unpublished data, 1975).
These techniques led to an unexpected and important discovery in late 1974 when Dubois in
France, using immunofluorescence, found somatostatin immunoreactivity in discrete cells of the islets
of Langerhans in several species. 35 This finding was
rapidly confirmed in isolated islets with a specific
radioimmunoassay. 36 Somatostatin was also found
scattered throughout the gastrointestinal tract with
unusually large amounts in the gastric antrum, 37 and
in addition was found in numerous extrahypothalamic areas of the central nervous system, 36 ·38 with
especially large concentrations in the septum and preoptic area, the thalamus, and the cortex. The highest
concentration of somatostatin in the hypothalamus
has been localized to the median eminence and the
a rcuate nucleus. 38 Definitive proof that extrahypothal a mic material with somatostatin immunoreactivity is identical to hypothalamic somatostatin
awaits amino acid sequence determination . The material does appear to have biological activity, however, as extracts of frog pancreas with a high content
of somatostatin immunoreactivity have been found
to inhibit growth hormone secretion. 39
I mmunofluorescent techniques were also used to
show that the cells containing somatostatin immunoreactivity in islets and gut were of the D-type. 40 D
cells comprise about 5% to 10% of the mammalian
islet cell population and tend to occur in close proximity to glucagon-containing A cells. In the mouse
and rat, for instance, A and D cells form a rim of
tissue around a central core of B cells. 41 In the horse,
however, there is a central mass of A and D cells with
peripheral cells being B cells, and in man A and D
cells occur together next to capillary walls. The physiological importance of this distribution is as yet unknown, but it seems likely that there is some unique
interaction between A a nd D cells.
An exception to the above pattern is found in
birds which have a population of islets, called light
islets, with D cells and B cells, but almost no A cells. 42
There are also, however, dark islets containing both
A and D cells and few B cells. Birds are also unique
because their pancreases contain high concentrations
of glucagon and somatostatin compared to mam-
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mals, 43 ·44 but the significance of this can only be speculated upon.
It was assumed by many that normal islet D cells
contained gastrin, largely because the cells of gastrincontaining tumors of the Zollinger-Ellison syndrome
have D-cell-like morphology. Some workers have
found gastrin immunoreactivity in islet tissue, 45 but a
recent thorough study has been unable to confirm
this .46 Thus, the origin of the gastrin-containing cells
of the Zollinger-Ellison syndrome remains undiscovered.
There has been discussion about whether somatostatin in extrahypothalamic cells is synthesized in
situ or taken up following secretion by the hypothalamus. The latter possibility seemed less likely because
of somatostatin's instability in blood and the finding
that the concentration of somatostatin in islets is
comparable to that found in the hypothalamus. Recent studies in the angler fish indicate that somatostatin is synthesized in islets. The angler fish is unique as
it has enormous (100 to 200 mg) islets which can
easily be dissected free and contain no pancreatic
exocrine tissue. lmmunohistochemical studies have
shown that approximately 30% of the cells contain
somatostatin, 20% contain glucagon, and 35% contain insulin. Islets were incubated with the labeled
amino acids 3H-tryptophan and 35 S-cystine, and islet
proteins were separated with column chromatography (P-10) and polyacrylamide gel electrophoresis
(pH 9.5). Clear peaks of radioactivity were found in
fractions containing the largest quantity of somatostatin immunoreactivity. 47 Synthetic cyclic somatostatin migrated into the same fractions . Thus there
is now good evidence that somatostatin is synthesized
in situ in islet tissue and there is also preliminary
evidence that there is a larger precursor form of
somatostatin (prosomatostatin ). Precursor forms
have been described for a number of other peptides
including insulin and glucagon .
There is currently great interest in defining the
characteristics of the secretory control of somatostatin as this should help solve some of the puzzles about
its physiological role. Data is fragmentary, but studies by G. Patton and co-workers 48 and E. Samo ls
and co-workers 49 ·50 in the isolated perfused canine
and rat pancreas now show that somatostatin secretion can be stimulated by glucagon and arginine.
The present interpretation is that glucagon probably
has a direct influence upon the D cell, and that the
arginine effect may be indirect, acting via local secretion of glucagon by the A cell.
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Somatostatin's contribution to the pathophysiology of diabetes has yet to be elucidated, but some
provocative information is available. Following the
induction of diabetes in rats with the B-cell toxin,
streptozotocin, a significant increase of islet somatostatin content was found using radioimmunoassay
techniques. 51 This author has observed (unpublished
data, 1976) that increased somatostatin in extracts of
whole rat pancreas has been found with streptozotocin, as well as with alloxan, a different B-cell toxin.
With immunofluorescent techniques it has been possible to show both hypertrophy and hyperplasia of
islet D cells not only in streptozotocin diabetic rats
but also in tissue from two juvenile-type human diabetics.52 These findings may be a secondary phenomenon related to the hypersecretion of glucagon, or
perhaps the hyposecretion of insulin known to occur
in diabetes, or to some other factor. The critical
question is whether there is increased islet somatostatin secretion leading to reduced insulin secretion.
Also, even though diabetics secrete excessive
amounts of glucagon which contribute to hyperglycemia, they might secrete even more glucagon were it
not for D-cell secretion of somatostatin. Therefore,
the D-cell hypertrophy could have either a beneficial
or detrimental influence upon diabetes.
An understanding of somatostatin's physiologic
importance may help us make sense of what is occurring in disease states. There is good reason to think
that somatostatin's effects are exerted locally. It
seems no accident that cells containing somatostatin
are located in close proximity to cells capable of
responding to somatostatin. Because of this proximity and because of somatostatin's instability in blood,
it would seem inefficient for this peptide to be transported through the circulation to distant organs. Unfortunately, it has not yet been possible to measure
physiological levels of somatostatin in plasma. Local
secretory mechanisms are probably important in
many organs, but islets are particularly intriguing.
There is now good evidence that local secretion by
autonomic nerve terminals of norepinephrine and
acetylcholine can influence both glucagon and insulin
secretion. 53 Some data suggest that local insulin secretion suppresses glucagon release from A cells 54 and
there is now reason to suspect that glucagon may
stimulate insulin release, 55 that somatostatin may inhibit the secretion of insulin and glucagon, and that
glucagon may stimulate somatostatin secretion. The
potential interactions which take place in islet interstitial spaces may be extraordinarily complex and
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difficult to clarify. Another possible way in which
different islet cells could communicate is through gap
junctions. Small molecules have been shown to move
from the cytoplasm of one cell into the cytoplasm of
another through these structures. Gap junctions have
been described as otcurring between B cells, and also
between A and B cells, 56 but thorough studies of
possible D-cell gap junctions are not yet available.
Suggestions have also been made that there may be
important electrical interactions between islet cells.
Even though one can make many speculations
about the possible importance of somatostatin in islets and the gastrointestinal tract, no definitive effects
have been elucidated. There is, however, evidence
that somatostatin exerts a physiological influence on
the pituitary. Injections of somatostatin antiserum
into rats led to increases in growth hormone and TSH
secretion, presumably by neutralizing somatostatin in
the hypothalamic-hypophyseal portal circulation. 57 •58
The finding that somatostatin is distributed throughout extrahypothalamic areas of the central nervous
system raises important questions about somatostatin's possible role as a neurotransmitter. There is also
much curiosity about the evolution and embryology
of somatostatin, particularly since its presence is
found in such diverse areas as the central nervous
system, pancreatic islets, and gut. It is worth noting
that another peptide, substance P, has recently been
found in various parts of the brain including the
hypothalamus, and the gut. 7
It was predictable that a "somatostatinoma"
would eventually be found, and 0. P. Ganda and
associates 59 indicate that it has been. A 46-year-old
woman with an eight-year history of well-documented diabetes mellitus was found to have a pancreatic islet cell tumor during a cholecystectomy.
Clinically there was no evidence of its being an insulinoma, glucagonoma, or a tumor of either the
Zollinger-Ellison or pancreati~ cholera (Verner-Morrison) type . Ultrastructurally the majority of the cells
appeared to be of the D-type. The somatostatin content of the tumor was remarkably high (301 ng/ mg of
tissue), and the content of insulin, glucagon, gastrin,
and vasoactive intestinal peptide was negligible.
Pathologically the tumor was judged to be a lowgrade malignancy, and metastatic tissue was found in
one of the 38 resected lymph nodes. Remarkably,
following surgical removal of the entire tumor, glucose values returned to normal and have remained so
for 16 months (a recent fasting blood sugar was 73
mg/ lOOml and two-hour postprandial was 70

mg/ IOOml ). We hypothesized that the patient was
diabetic because of the continued secretion of large
amounts of somatostatin by her tumor . As mentioned above, experimental infusions of somatostatin
in normal subjects produce a fall of blood glucose;
this drop, however, is only transitory, lasting for a
few hours; with a longer infusion, hyperglycemia develops. Studies of insulin, glucagon, and growth hormone secretion in response to an arginine infusion
were done prior to surgery and the response of each
hormone appeared to be diminished, as one might
expect with chronic somatostatin exposure. Unfortunately, it was not possible to repeat the study following surgery . When a patient is found to have an
apparently non-functionirig pancreatic tumor of the
islet cell type, especially if diabetes is also present, the
possibility of a somatostatinoma shot.lid be considered .
Somatostatin has proved to be infinitely more
interesting than anyone might have imagined at the
time of its discovery in 1973. Current interest in this
unique peptide is focused upon its potential role in
the pathophysiology and therapy of diabetes mellitus.
It is probable that somatostatin also will come to
occupy an increasingly prominent place in such diverse disciplines as cell biology, the neurosciences,
endocrinology, and gastroenterology.
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Insulin Receptors
WILLIAM G. BLACKARD, M.D.

Director, Clinical Research Unit and Chairman, Division of Endocrinology and Metabolism, Department of
Medicine, M edica/ Co//ege of Virginia, H ea/th Sciences Division of Virginia Commonwealth University,
Richmond, Virginia

Much of the emphasis in the pathogenesis of
diabetes mellitus has justifiably been placed on the
endocrine gland, the pancreas. Extensive studies on
the biosynthesis and release of insulin from the beta
cell, bihormonal control of metabolism by insulin
and glucagon, and more recently the role of somatostatin have attracted the attention of students of the
subject; but considerable evidence exists to suggest at
least some role of tissue resistance to insulin in the
pathogenesis of this disorder. There have been many
advocates for extra-pancreatic factors causing diabetes. One of the first was Mirsky, who proposed that
diabetes might be due to excessive amounts of hepatic
insulinase, an enzyme which degrades insulin.' Vallance-Owen suggested that a circulating insulin antagonist labeled synalbumin might be the cause of
insulin resistance in diabetes. 2 This factor was later
shown to be an artifact. Others, such as Antoniades,
proposed that insulin might circulate predominantly
in a bound form in diabetic subjects and thus not
exert full biologic activity. 3
The most articulate spokesman for a role of
insulin resistance in diabetes mellitus in recent years
has been Gerald Reavan, and his group from Stanford University, who bases his theory on two observations. The first is that a large number, if not the
majority , of adult onset diabetics have increased circulating insulin concentrations rather than decreased
concentrations as had been expected. This was first
observed by Yalow and Berson shortly after the perfection of the radioimmunoassay for in sulin. 4 HyperCorrespondence and reprint requests to Dr. William G.
Blackard, Clinical Resea rch C enter, Box 155, Medical College of
Virginia, Richmond, Virginia 23298.

12

insulinism in diabetics has since been confirmed by
many investigators. A second observation supporting
the role of insulin resistance in diabetes is that of
"glucose impedance" in diabetic patients. Glucose
impedance was demonstrated by Reaven and colleagues5 by infusing glucose and insulin at a constant
rate in diabetic and non-diabetic subjects whose endogenous insulin release had been shut off by administration of epinephrine and propranolol. New steady
states for glucose and insulin were achieved in both
groups, with comparable insulin concentrations in
diabetics and non-diabetics, whereas the new steady
state glucose concentration was considerably higher
in diabetic subjects than in non-diabetic subjects.
These excellent studies indicated that for a given concentration of insulin, the blood glucose-lowering effect was less in diabetics than in non-diabetic subjects. More recently, Reaven and Olefsky have
suggested that insulin resistance in diabetic patients
might be due to a decrease in the number of insulin
receptors 6 by showing a decrease in the number of
insulin receptors on circulating monocytes in diabetic
patients compared to those on monocytes of nondiabetic subjects. Additionally, treatment of their
diabetic subjects with an oral hypoglycemic agent
resulted in a return to normal of the number of
insulin receptors on peripheral monocytes. 7 A thorough understanding of these latter observations and
their obvious, important implications for the pathogenesis of diabetes requires a certain knowledge of
the insulin receptor and of recent advances in the
field of receptor technology.
Properties of the insulin receptor are shown in
Table I. As is the case with other polypeptide hormones, the receptor for insulin is located on the cell
MCV QUARTERLY 13( 1): 12-16, 1977
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TABLE I
Properties of Insulin Receptors
A) Located on cell membrane
B) Unevenly distributed a nd may occur in clumps
C) Protein with mo! wt approx. 300,000-Tetramer consisting of monomers of 75,000 mol wt each
D) Continuous synthesis and degradation with relatively
slow turnover rate-2%/ hr
E) Presence of insulin receptor on cell membrane requires
protein synthesis and microfilament integrity

membrane. Evidence for intracellular distribution of
insulin receptors is very scant; they are not evenly
distributed over the cell surface but rather occur randomly and in clumps at times. 8 Present evidence suggests that the insulin receptor is a protein with molecular weight of approximately 300,000. Studies
performed at the National Institutes of Health from
Dr. Jesse Roth 's laboratory suggest that the insulin
receptor is a tetramer consisting of monomers of
75,000 dalton units each. Although the turnover rate
is low compared to many biologic processes (2% per
hour), continuous synthesis and degradation of the
insulin receptor occurs. Studies with inhibitors of
protein synthesis and microfilaments such as puromycin and cytochalasin respectively indicate that
protein synthesis and microfilarhent integrity are necessary for the presence of insulin receptors on the cell
membrane. 9 Inhibitors of microtubular function surprisingly had no effect on insulin receptors. 9
Knowledge of three concepts involving the insulin receptor (Table 2) is of critical importance in
interpreting studies in which receptor number and
affinity have been determined. The number of receptors per cell varies with the parti~ular cell being studied . However, for the peripheral monocyte, which is
the most commonly studied cell in man because of its
accessibility, the numbers of receptors vary between
15 ,000 and 30,000 per cell. Clearly, only a fraction of
the receptor sites must be occupied for biological
activity, and the number of occupied sites required
for the different activities of insulin may vary . For
example, dose response data suggest that fewer sites
must be occupied to inhibit lipolysis than to stimulate
glucose oxidation. Thus, many of the insulin receptors on the cell surface will be spare or unused receptors. Recent investigations have even shown that
some of these receptors rnay serve as a peripheral
reservoir for insulin, · releasing intact insulin under
appropriate circumstances. 10
A second concept which is probably the most

13
important in understanding current receptor studies
is that insulin inhibits insulin receptor number. Experiments by Gavin et al 11 demonstrated that preincubation of cultured lymphocytes with physiological concentrations of insulin reduces the
number of insulin receptors on these cells. An obvious corollary of this finding would be the presence
of decreased insulin receptors in states of hyperinsulinism such as obesity and some forms of diabetes .
Although not reported yet, reduced insulin receptors
would be anticipated in patients with islet cell tumors. Thus, reduced receptor number might offer
some protection to the patient with an islet cell tumor.
The third important concept in understanding
insulin receptors is that of negative cooperativity. 12
Simply stated, this concept refers to site interactions
on the cell surf(\ce by which affinity of the receptor
for insulin is decreased as increasing numbers of receptors are occupied. This phenomenon might also
be considered a homeostatic mechanism which protects the individual from the effects of hyperinsulin1sm.
The insulin receptor perceives and either directly
or through a transducer substance influences the effector for a specific activity. Insulin binding is the
first step in biological activity of the hormone. Although not all receptors are required for biological
activity, more receptors increase the likelihood of
binding for a given concentration of insulin . Binding
of insulin to its receptor is therefore determined by
insulin concentration, receptor number, and receptor
affinity. Radioimmunoassay techniques for the measurement of insulin have been available for years;
now methods are available to measure insulin receptor number and affinity.
As mentioned the most accessible cells for measuring insulin receptors in vivo are peripheral monTABLE 2
Important Concepts Involving Insulin Receptors
A) Spare receptors
I) Number of receptors per cell va ries with cell type
Peripheral monocytes have 15,000-30,000 receptors
per cell
2) Only small percentage of receptors must be occupied
for biologic act ivity
3) Spare receptors may serve as peripheral insulin
reservoir
B) Feedb ack inhibition of insulin receptor number by
insulin
C) Negative cooperativity
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ocytes. These cells are obtained by Ficoll-Hypaque
separation of the buffy coat of centrifuged blood. To
determine receptor number and affinity, these cells
are incubated with labeled insulin and increasing
amounts of cold insulin, resulting in a binding curve
(Fig I). Applying Scatchard analysis to this data
results in a curvilinear plot (Fig 2B). Similar studies
with the growth hormone receptors, or other hormones not showing negative cooperativity, produce a
linear Scatchard plot (Fig 2A ). Although th,e favored
interpretation of the curvilinear Scatchard plot for
insulin receptors is negative cooperativity, the possibility that two types of insulin receptor sites (broken
lines Fig 2) exist cannot be eliminated from present
data. Employing Scatchard analysis, the number of
receptors is calculated from the amount of bound
insulin where the plot crosses the X axis . The slope of
the plot reflects affinity, and new graphic analyses are
available to express affinity even from a curvilinear
plot.1a
Employing these techniques, insulin receptor
number and affinity can be determined. The factors
influencing affinity and receptor number are shown in
Table 3. Some of these have already been discussed.
One of the most important determinants of affinity is
pH; its effect on insulin binding to receptors is shown
in Figure 3. For both human monocytes and cultured
lymphocytes, reducing pH from 7.4 to 6.8 results in
greatly depressed insulin binding ahd may contribute
to the insulin resistance observed in severe diabetic
ketoacidosis.
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Fig 2-Scatchard analysis of binding data. B/ F = bound / free
radioactive ligand. Horizontal axis (Ro) is amount of ligand bound
to receptor in molar quantities. A. Scatchard plot for hormone not
exhibiting negative cooperativity; B. Plot is for hormone exhibiting
negative cooperativity or having two different receptor sites. Insulin receptor studies show curvilinear plot as in B.

The major factor so far uncovered altering insulin receptor number is insulin acting in a type of
feedback mechanism to inhibit insulin receptor number. Thus, as previousiy pointed out, reduced insulin
receptors are anticipated in obesity where insulin resistance and hyperinsulinism exist. Reduced insulin
receptors have indeed been shown to occur in obese
humans and animals. 1•- 16 In addition, dieting and
weight reduction result in normalization of the numbers of insulin receptors . 13 It is debatable whether
reduced receptor concentration is primary, resulting
in insulin resistance and hyperinsulinism, or whether
insulin resistance due to some other factor is primary,
causing hyperinsulinism and, secondarily, reduced insulin receptors .
Returning to Reavan and Olefsky's observations
in non-obese diabetic subjects, 6 it is not clear whether
the reduced insulin recej".ltor number is due to the
hyperinsulinism exhibited by this group [fasting im·
munoreactive insulin (IRI) 20 ± 2 versus IO ± I in
normals] or whether it might be primary and thus be
important pathogenetically. Nevertheless the decreased insulin receptors observed in the diabetic sub-
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TABLE 3
Determinants of lnslllin Binding to Tissues

u

l. Receptor affinity
0.1
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Insulin {ng/ml)

Fig !-Insulin binding to peripheral monocytes. 20 X 10' mononuclear cells ( 14% monocytes) were incubated in 0.5 ml buffer
containing 50-100 pg 125 !-insulin and increasing amounts of unlabeled insulin to give the final concentration indicated in the figure .
After 3 hours incubation, 200 ul aliquots were centrifuged, aspirated , and the sediment counted.
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PH
Temperaiure
Ionic strength
Receptor occupancy (Negative cooperativity)
II. Receptor number
Insulin decreases receptor number
11 l. l nsulin concentration
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Fig 3-Effect of pH on insulin binding to receptors. Maximum
binding refers to percent of 125 1-insµlin bound to receptors in the
absence of unlabeled insulin. For peripheral cells 20 X IQ' , mononuclear cells (14% monocytes) were used; cultured lymphoblastoid cells (IM-9) were used at 3.0 X 10' cells per ml concentration.

jects in Reaven and Olefsky's study would certainly
contribute to the insulin resistance observed. The
return of receptor number to normal with chronic
sulfonylurea treatment 7 might in similar fashion be
attributed to the reduced ' Insulin concentrations in
well-controlled diabetics on chronic sulfonylurea
therapy.
Although the role of reduced insulin receptors in
the pathogenesis of diabetes mellitus is equivocal, a
rare diabetic syndrome recently reported is clearly
related to decreased insulin receptors. 17 In several
patients with other evidence of immunologic disease
associated with severe insulin resistance, an antibody

NORMAL SUBJECT
PATIENT

Fig 5-Effect of serum preincubation on insulin binding to cultured lymphobl as toid cells (IM-9). IM-9 cells were preincubated
with buffer , normal serum, or serum from insulin-resistant patient
for 60 min, washed twice, and resuspended in 0.5 ml buffer at final
concentration of 3 X 10' cells p~r ml. Binding curves were then
obtained on these cells.

to the insulin receptor has been demonstrated. Since
this report we at the Medical College of Virginia have
had the opportunity to study two patients with this
syndrome. One of the patients requiring over 2,000
units of insulin daily had a strongly po~itive antinuclear antibody as the only other manifestation of
autoimmunity; the second patient had a sclerodermalike illness and required 1200 units of insulin daily.
Insulin binding curves by peripheral monocytes from
one of these patients is shown in Figure 4. That a
serum factor was responsible for the decreased binding was indicated by studies in which cultured lymphocytes (IM-9) were preincubated with the patient's sera (I : I 00) and then used for binding studies
(Fig 5) . Scatchard analysis (Fig 6) revealed the decreased binding to be due to a reduction in numbers
of insulin receptors . Studies, not shown, in which

IM · 9 CELLS PRE INCUBATED WITH

HEPES
NORMAL SERA 1'2
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Fig 4-1 nsulin binding to peripheral monocytes from normal subject and patient with antibodies to the insulin receptors. Details as
for Fig I.
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Fig 6-Sc11tchard analysis from binding data shown in Fig 5.

16

BLACKARD: INSULIN RECEPTORS

cultured lymphocytes were preincubated with IgG
fraction of the patient's sera exhibited the same phenomenon, suggesting that the serum contained an
antibody to the insulin receptor.
In summary, techniques are now available for
measuring insulin receptors in vivo. So far, reduced
insulin receptors have been observed in obese persons
and in a selected group of adult onset diabetic patients. The pathogenetic significance of the latter observation is uncertain and may possibly be a manifestation of the high insulin concentrations in these
diabetics. However, a rare diabetic syndrome in
which severe insulin resistance due to antibbdies to
the insulin receptor has been reported and is now
corroborated by our findings in two patients.
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Why Control Diabetes?
HAROLD RIFKIN, M.D .
. Clinical Professor of Medicine, Albert Einstein College of Medicine, New York, New York , and Senior
Diabetologist, Montefiore Hospital Medical Center, New York, New York

The definition of diabetes control varies widely
among specialists of the disease. Proponents of
"good" control believe that the goals of appropriate
therapy for diabetes should include an all-out effort
to obtain levels of fasting and postprandial blood
glucose as close to those in the non-diabetic as possible. Certainly, good control has been proven to
accomplish the following :
1. Prevention of ketoacidosis
2. Prevention of severe hypoglycemia
3. Decrease in perinatal mortality and morbidity
4. Promotion of normal growth and development of the juvenile diabetic
5. Prevention of, or inhibition of, infection
The evidence that hyperglycemi~ is responsible
for vascular complications, particularly microvascular disease, and that good control will prevent
or inhibit the rapidity of the development of this
pathologic process, or even reverse it, is the basis of
this presentation.
·
At the outset, however, it must be appreciated
that retinopathy, nephropathy, neuropathy, and
large vessel disease may be the presenting manifestations of diabetes, and that it is possible to have extensive vascular complications in the presence of relatively mild glucose intolerance. Furthermore, 20% of
juvenile-onset type, ketosis-prone diabetics of more
than 25-years duration with continuous hyperglycemia do not have clinically impressive retinopathy

This is an abstract of the lecture given by Dr. Rifkin at the
symposium, Diabetes 1976.
Correspondence and reprint requests to Dr. Harold Rifkin,
Montefiore Hospital Medical Center, Bronx, New York 10467.
MCV QUARTERLY 13(1): 17-18.1977

or nephropathy. Also, it has been noted that large
vessel disease or neuropathy is absent in 20% to 40%
of insulin-dependent diabetics.
The evidence for good control is largely based on
the following observations:
1.
2.
3.
4.
5.

Clinical studies
Animal studies
Histologic and electron microscopic data
Biochemical studies
Altered coagulopathy, viscosity, and hypoxia

Recent studies in well-controlled juvenile diabetics indicate that serial biopsies of quadriceps muscle
have demonstrated "thinning" of previously thickened capillary basement membrane, in contrast to
persistent and increasing thickening of capillary basement membrane in poorly controlled diabetic patients. In addition , it has recently been demonstrated
that diabetic vascular lesions developed in normal
kidneys transplanted into patients with diabetes mellitus after a period of two years, while transplanted
kidneys in non-diabetic control patients of the same
age and type remained unaffected; this also gives
great support to the concept of good control.
Animal studies with diabetic Chinese hamsters,
mice, rats, dogs, and monkeys have indicated that
good control with insulin therapy or islet transplantation prevents or reverses lesions in the eyes,
kidneys, or nerves.
Histologic and electron microscopic studies of
capillary basement membrane of muscle have given
conflicting results. One group of observers indicates
that basement thickening is already genetically predetermined, while other investigators relate capillary
basement membrane thickening to the duration of
diabetes. Methodology of technique, the patient' s
age, unknown duration of existing diabetes, and cri17
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teria for the diagnosis of diabetes have to be clarified
before coming to definitive conclusions.
Biochemical studies indicate that hyperglycemia
or insulin deficiency produces alteration in vascular
basement membrane composition, as well as accumulation of glucose-derived substances, such as sorbitol
in the lens of the eye, Schwann' s cell, and aorta.
Recently, an elevation of glycolysated hemoglobin
(HbAJc) has been noted in the blood of diabetic mice
as well as human diabetics. The glycolysation of hemoglobin appears to be a post-synthetic modification
of HbA which is dependent on the degree and duration of hyperglycemia.
Recent data reveal that platelet aggregation is
more intense in diabetic patients, with increased sensitivity of platelets to aggregation from adenosine
diphosphate (ADP) and epinephrine. This sensitivity
correlates with elevated levels of Von Willebrand factor, which in turn appears to be influenced by growth
hormone. Also, platelets from diabetic subjects are
more sensitive to arachidonic acid-induced aggregation, which can be abolished by aspirin, which is a
prostoglandin synthetase-inhibitor.
Spontaneous fibrinolytic activity of the blood is
abnormally low in persons with diabetes mellitus,
and implies a poor defense mechanism against fibrin
deposits in the vessel walls, which conceivably may
contribute to the development of diabetic micro-
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angiopathy. Increased red blood cell aggregation and
alterations in plasma protein changes in diabetics,
with their effects on blood viscosity and flow , may
also play a role in accelerating the rate of progression
of diabetic microangiopathy.
In addition, the decreased reactivity of HbAlc
with 2,3 diphosphoglycerate might impair oxygen unloading in diabetes, and contribute to tissue hypoxia,
which may have pathogenetic implications in the development of diabetic angiopathy.
Whether reversal of hyperglycemia, as well as
the use of agents to inhibit some of the above-described adverse effects of the diabetic milieu, may
affect the development of diabetic microangiopathy is
far from settled. Consideration must be given to more
intense regulation of dietary factors; use of the newer
oral hypoglycemic agents; administration of insulin
three or four times daily for better control; long-term
studies on the use of aspirin, and other platelet-aggregating inhibitors, as well as phosphate supplements;
availability and effectiveness of growth hormone inhibiting agents; the use of substances which can interfere with the post-ribosomal steps of basement membrane assembly; and finally , improvements in the
delivery of insulin, whether it be by better biomechanical engineering or by increased knowledge of
immunologic and other biologic defenses in the use of
islet or organ transplantation.

Insulin Treatment of Diabetes Mellitus
H. ST. GEORGE TUCKER, M.D.

Division of Endocrinology, Department of Medicine, Medical College of Virginia, Health Sciences Division of
Virginia Commonwealth University, Richmond, Virginia

Dr. Harold Rifkin*, has previously set forth the
reasons why we should try to keep the diabetic patient's blood sugar as near normal as possible. What
are the generally accepted standards of good diabetic
control?
Marble 1 considered control of the insulin-dependent diabetic good if the whole blood glucose before
meals was not over 130 mg% ( = serum glucose 150
mg%), the 24-hour urinary glucose did not exceed 5%
of the carbohydrate intake, and there was no ketonuria; Oakley et al2 defined satisfactory control as
blood glucose before meals of less than 150 mg% with
no hypoglycemia; Lewis et al, 3 in a recent paper
dealing with pregnant diabetics, recommended fasting blood glucose below 100 mg% and blood glucose
two hours after break fast below 160 mg%.
In some diabetics we can accomplish this type of
control; in others we cannot. The maturity onset
diabetic has some endogenous insulin under autoregulatory feedback control and, with a judicious diet
or with the addition of a sulfonylurea drug or some
exogenous insulin, near normal blood sugars can be
achieved. However, in the juvenile or young adult
onset diabetic, with little or no endogenous insulin, it
is very difficult, even with complicated schedules of
administration of insulin, to get blood sugars anywhere near normal without producing hypoglycemia.
A reasonable goal for every diabetic would be to
maintain blood sugars as near normal as possible
without producing hypoglycemia and without requiring a program so restrictive that it interferes with the
quality of life.

* see precedin g

abstract.

C orrespondence and reprint requests to Dr. H . St. George
Tucker, Di vision of Endocrinology, Box l l l , Medical College of
Virginia, Richmond , Virginia 23298.
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Figure l, taken from a paper by Molnar et al, 4
illustrates the daily variations in plasma insulin and
blood glucose throughout a 24-hour period in a normal individual. Meals, snacks, and standard exercise
periods are indicated. It is apparent that each feeding
is accompanied by a sharp peak in insulin secretion
which brings about disposal of ingested glucose and
amino acids, and limits the blood sugar rise.
It is obvious that no one injection of intermediate-acting insulin can in any way duplicate the
normal insulin pattern. At best an injection ofNPH®
or Lente® Insulin given before breakfast will be absorbed for the most part over the next 8 to 12 hours
when meals will be eaten, with some carry-over effect
during the night. As diabeticians we hope to accomplish blood sugar levels that average ;;omewhere near
normal, but obviously the blood sugar will rise too
high after meals and .may fall too low before the next
meal. Further leveling out may be accomplished by
the addition of between-meal and bedtime snacks.
We always insist on midafternoon and bedtime
snacks in every patient on NPH ® or Lente® Insulin.
Bressler and Galloway 5 some years ago called
attention to variations in the timing of effect of various insulins (Fig 2). Diabetics were divided into those
showing a normal (B) response, a transient (A) response, or a delayed (C) response to NPH® or Lente®
Insulin . Those with a normal response could be moderately well regulated with a single morning injection
of NPH® or Lente® Insulin . Those with a transient
response might benefit from a second small dose of
NPH® or Lente® Insulin before supper, and those
with a delayed response might require the addition of
regular insulin to the morning dose of NPH® or
Lente® Insulin . The reasons for this variation in the
timing of effect of the intermediate-acting insulins is
not known . One possible factor delaying the action of
19
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mortality and morbidity, 3 although better obstetrical
techniques for monitoring the pregnancy and timing
of delivery are equally important factors in the improved outcome in these patiepts. Thus a number of
schedules of insulin administration have been proposed as illustrated in Table 1. There is good rationale for each of these programs in a given situation,
although it is unlikely that any one type of progra m
will be best for all patients.
Attempts have been made to define complicated
dosage schedules even more rigidly. Lewis et al3 recommend the following formula for insulin administration for pregnant diabetics:
Morning NPH ®
Morning reg. ins.

Evening NPH®
Evening reg. ins. = I : I

o ~ ·

07

11

15

19

23

03

2: I

07

Morning total

Clock time
Fig I-Meal-to-meal <ind day-to-day variations in blood glucose
and immunoreactive insulin in a normal subject on two successive
days (solid line represents first day; interrupted line represents
second day). B = breakfast, L = lunch , Sk = snack, D = dinner,
Su = supper, E = exercise, one hour of walking.

insulin is its binding to antibodies, with subsequent
release, which prolongs the insulin effect.
Lukens, 6 Forsham, 7 and others pointed out some
time ago that multiple injections of regular insulin
before meals, perhaps accompanied by one or more
injections of longer-acting insulin to control overnight blood sugar, would more closely resemble normal physiology and would be likely to give better
control than a single injection of long- or intermediate-acting insulin. Indeed it is doubtful whether
the medical profession did diabetic patients any favor
when some years ago it abandoned multiple insulin
injections in favor of the once-a-day injection of
longer-acting preparations. Once the diabetic public
became accustomed to the single morning injection it
was difficult to persuade patients to go back to multiple injections and, by and large, doctors hav~ seldom made the effort.
Recently there has been a renewal of interest in
the use of multiple injections of regular insulin to
accomplish more physiologic control, especially since
reports from Paris by Job et a1 8 seem to indicate that
such regimens in juvenile diabetics result in better
control and in less progression of retinopathy . Also,
especially good control in pregnant diabetics with
multiple injections appears to result in lower infant

=

2 X evening total

I have tried this schedule with several pregnant diabetics with quite varied results. I think the reasoning
is right, but it should be remembered that no two
diabetic patients will respond in exactly the same
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Fig 2-Blood sugar responses to a single daily dose of NPH ®
Insulin.

TUCKER: INSULIN TREATMENT OF DIABETES MELLITUS

TABLE I
Various Schedules for Insulin Administration

Breakfast

Lunch

Afternoon
Snack

Supper

Bedtime
Snack

N

R+ N
N

R
R

R
R

R +N

N
N

R +N
R+N

(N = _NPH'" or Lente"' Insulin. R = regular or crystalline
zinc insulin.)

way-there are just too many variables. Some of
these are listed in Table 2.
How then should one approach if)sulin treatment in any given patient? Two basic principles are
helpful: (I) analyze what kind of diabetic the patient
is, and (2) keep the variables at a minimum.
The first principle means to try to form some
idea of how much endogenous insulin the patient has
from evaluation of the age of onset of the diabetes,
his or her weight at onset, and the severity of symptoms at onset, especially weight loss. Onset of diabetes early in life, severe polyuria and polydipsia, and
especially weight loss from uncontrolled diabetes,
usually indicate total or near total insulin deficiency.
If the patient has been on treatment, the diabetician
should also consider the occurrence of ketoacidosis

TABLE 2
Variable Factors Limiting Good Blood Sugar Control
with Exogenous Insulin
I.
2.
3.
4.

Variations in food intake
Variations in exercise
Emotional factors and other stresses
Factors affecting the avai lability and effectiveness of
administered insulin:
(a) variab le absorption rates from injection site
(b) variable antibody titers and uncertain rates of release
of insulin from antibodies
(c) variations in receptor binding sites and in their
affinity for insulin
5. Variations in glucagon secretion
6. Hypoglycemia with rebound hyperglycemia caused by
counter-regulatory factors
7. Exogenous insulin is delivered into systemic circulation
and not primarily into portal circulation and to the liver
as is endogenously secreted insulin
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or frequent hypoglycemic reactions, both of which
suggest that the patient has little or no endogenous
insulin. If the patient has been controlled in the past
on oral agents he or she must have had some endogenous insulin at that time.
The second principle, keeping the variables at a
minimum, means trying to get the patient to maintain
reasonably constant eating habits and exercise patterns as well as simplifying the insulin schedule until
the need for multiple doses becomes apparent. In
general, begin with a single dose of NPH® or Lente®
Insulin every morning, perhaps 20 units if the patient
has never before taken insulin. Instruct the patient in
a proper diet, which probably should include both
afternoon and evening snacks, for his or her weight
and activity . The patient may continue working but
should test his or her urine four times daily, before
meals and at bedtime. If the patient continues to spill
sugar, increase the insulin by 5 units every four or five
days until some negative urine tests are obtained.
Check the blood sugar at the time of the negative
urine test, and if this is still high, continue to increase
the insulin until the blood sugar is in the desired
range. If any hypoglycemic reactions occur, the insulin dose should be reduced . As the patient approaches control the urine tests should be determined
from second voidings whenever the first voiding contains sugar.
Many diabetics will come under satisfactory
control with a single morning dose of NPH® or
Lente@ Insulin. If glycosuria or hyperglycemia persists before breakfast, with negative tests in the afternoon, the patient may be classified as a transient
responder, and a second small dose of N PH® or
Lente''9 Insulin should be added before supper. If the
morning test is repeatedly negative but glycosuria
persists before lunch, the patient may be a delayed
responder, and regular insulin can be added to the
morning NPH@.
If the desired degree of control is not achieved by
these measures, both regular and NPH ® Insulin may
be given twice daily. In general the indications for
administration of such multiple doses would follow a
schedule such as in Table 3, as suggested by Oakley et
al.2
In a highly reliable and highly motivated patient,
such as a pregnant diabetic, this type of program may
succeed ; or a highly obsessive patient may religiously
seek perfect i:.;ontrol. Unfortunately most patients are
not so reliable, and the obsessive ones usually end up
making themselves hypoglycemic.
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TABLE 3
Management of the Severe Diabetic with Twice Daily
Injections of Re~ular and NPH® Insulin

Insulin
Morning RI
Morning NPH ®
Evening RI
Evening NPH '"'

Peridd of
Maximum Action

Timing of urine or
bldod sugar for
dose adjustment

Breakfast to lunch
Lunch to supper
Supper to midnight
Midnight to breakfast

Pre-lunch
Pre-supper
Bedtime
Pre-breakfast

What do you do with the patient who never
shows any consistent pattern? You look for such
variables as food intake, exercise, emotional upsets,
and other factors . Hypoglycemia, recognized or unrecognized, is the cause of much brittleness. For every recognized hypoglycemic reaction, the brittle
juvenile diabetic has ten other occasions when the
blood sugar is quite low without his knowledge, and
each may be followed by rebound hyperglycemia.
You must learn to recognize this pattern and to reduce insulin accordingly. Tables 4 and 5 illustrate two
such patients.
Table 4 is a record of the urine sugars on a 23year-old dental student with diabetes of two years'
duration, during which he took 12 units of Semilente® and 20 units of Lente® Insulin daily. He was on
a 2500-calorie diet including three main meals and
midafternoon and bedtime snacks. He was extremely
conscientious and liked to keep all his urine tests
negative. To keep himself in physical trim he ran two

TABLE 4
Insulin Dosage and Urine Tests Showing Glycosuria
Following Asymptomatic and Unrecognized Hypoglycemia
J.S. (Male, 23)
Insulin
12 SL ± 20 L

Urine sugars
7

II

4

9

N
N
4+
N

N
N
4+
N

2+

3+
3+

N
N
N
N
N
N
N
N
N

N
N*
N
N*
N
N*
4+
N
N

N

3+
4+
N

N
I+
N

* Ran approximately 2 miles
(SL = Semilente"' Insulin. L = Lente® Insulin .)

miles several times a week, and because of his busy
schedule chose the late evening as the time for his
exercise. He was not conscious of any hypoglycemic
reactions, but he invariably showed unexpected sugar
in his urine on the mornings after running; when he
had not run the night before, his tests were almost all
negative. It became apparent that the additional exercise was causing undetected hypoglycemia during the
night, followed by rebound hyperglycemia and glycosufia the next day, the so-called Somogyi effect
caused by the secretion of epinephrine, glucagon, cortisol, and growth hormone in response to hypoglycemia. The situation was corrected by insisting that
he take sizable extra feedings just before and just
after his nocturnal exercise periods; this prevented
the hypoglycemia and its consequent rebound.
The Somogyi rebound hyperglycemia following
hypoglycemia is most often seen in the brittle juvenile
diabetic, but can be observed in any insulin-dependent diabetic. Table 5 shows the record of urine tests
on a 72-year-old diabetic taking 32 units of NPH®
Insulin daily. He also was very conscientious and
very careful about his diet. After a series of days with
all negative urine tests, he showed unexpected 4+
sugar at noon on Aug 29 and Aug 30, with sugar

TABLE 5
Insulin Dosage and Urine Tests in an Older Diabetic
Showing Glycosuria, Probably Representing Rebound
After Unrecognized Hypoglycemia
J.Y.C. (Male, 72)
NPH"'
8/ 27
8/ 28
8/ 29
8/ 30
8/ 31
9/ 1
9/ 2
9/ 3
9/ 4
9/ 5
9/ 6
9/7
9/ 8
9/ 9
9/ 10
9/ 11
9/ 12
9/ 13
9/ 14

32

30

7

12

5

9

N
N
N
N
N
N
N
tr
N
N
N
N
N
N

N
N
4+
4+
N
tr
N
tr
N
N
N
N
tr
2+

N
N
I+
4+
N
tr

4+
N

3+

3+

N

2+
tr

3+
I+
N

3+
N

3+
N
N
N
N
N
tr
N
N
4+
N
N
N

3+
4+
N
N
3+
4+
N
N
N
N
4+

3+
4+
4+
N
N
N
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persisting during the rest of the day. Questioning
revealed no dietary indiscretions, no variation in exercise, and no emotional upsets or other stresses to
account for the glycosuria. Although he was unaware
of any hypoglycemic symptoms, it seemed inconceivable that the dose of insulin which had kept his tests
all negative over the previous days could be so inadequate on these days. I suspected unrecognized
hypoglycemia and reduced his NPH® Insulin to 30
units. The urine tests improved and remained all
negative until Sep 8 when he again began to show
sugar in the evening test. Not shown in Table 5 is the
fact that his NPH® Insulin was lowered again to 28
units and later to 26 units with improvement each
time and, finally, all negative urine tests. He remained
on 26 units of NPH ® for several months, then began
to spill sugar in all specimens; the NPH® Insulin dose
has been gradually raised again to 30 units with good
control. The reason for these swings in insulin requirement over periods of several months is unknown. Some patients go through cycles when their
insulin requirement goes up or down for no apparent
reason; these may be over months or over shorter
periods. All we can do is to try to keep pace through
adjustments in insulin dose.
When the patient alternates between good days
and bad days, with lots of sugar or no sugar, suspect
hypoglycemia with rebound. In any event you should
adjust the patient's insulin dose to his or her better
days and not try to give more for the bad days or you
will surely produce hypoglycemia.
The bane of the diabetician 's existence is the
obese patient on insulin. If these patients could have
been made to reduce in the beginning, many of them
would not have needed insulin. Once on insulin, lipolysis is inhibited, weight reduction becomes even
more difficult, and these patients tend to gain more
weight which increases insulin resistance, creating a
vicious circle of upward spiraling weight and insulin
dosage. In this instance it may be better to cut back
the insulin dosage and let the patient spill sugar until
somehow he or she can be persuaded to really limit
food intake. There is no satisfactory answer to this
problem unless the patient loses weight.
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In summary, I believe in aiming for the best
possible control for each patient through an empirical approach which seeks to arrive at the best schedule for the individual patient. We want especially
tight control for the pregnant diabetic, and for this
patient it is likely that multiple insulin injections are
needed . If further experience confirms the benefits of
multiple injections for juvenile patients, this type of
treatment may a1so be indicated for these patients.

Figure 1 is reproduced with permission from Mayo Clinic
Proceedings (47:709-719, 1972).

Figure 2 is reproduced with permi ssion from Medical Clinics
of North America (55:861-868, 1971 ).
Table 3 is reproduced with permission from Diabetes
( 15:2 19-222, 1966).
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Oral Hypoglycemic Agents
HAROLD RIFKIN, M.D.
Clinical Professor of Medicine, Albert Einstein College of Medicine, New York, ·New York, and Senior
Diabetologist, Montefiore Hospital Medical Center, New York, New York

The pharmacology of the two general groups of
oral anti-diabetic agents, namely the sulfonylureas
and biguanides, are briefly discussed here. The sulfonylureas have a common hypoglycemic core. These
sulfonylurea compounds can be divided into short,
intermediate, and long-acting agents, with varying
half-lives, and duration of action. Therapeutic doses
of sulfonylureas have produced wide variations in
serum levels depending upon the rates of absorption,
rates of metabolism, renal clearance, and degree of
protein-binding. Tolbutamide is a short-acting agent
metabolized by the liver to inactive compounds
which are excreted by the kidney; it has a half-life of
four to five hours, a duration of action of approximately six to ten hours, and is given in divided daily
dosage. Acetohexamide and tolazamide, the intermediate-acting compounds, are metabolized by the
liver. Approximately 75% of acetohexamide is metabolized to another hypoglycemic compound, and
tolazamide is metabolized to several hypoglycemic
products. The duration of the action of these agents is
approximately 10 to 16 hours; they are administered
either once or twice daily . Chlorpropamide is only
slightly altered, less than l % being metabolized,
probably in the liver; it is firmly bound to protein, is
dependent on renal excretion for clearance, and, as it
has a duration of action varying from 35 to 72 hours,
it is given only once daily.
Sulfonylurea compounds appear to exert their
primary action through direct stimulation of pancreatic insulin secretion. Peripheral insulin levels correlate with blood sugar levels during acute therapy,
This is an abstract of the lecture given by Dr. Rifkin at the
symposium, Diabetes 1976.
Correspondence and reprint requests to Dr. Harold Rifkin,
Montefiore Hospital Medical Center, Bronx, New York 10467.
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but do not appear to correlate with blood sugarlowering effect of chronic drug therapy. Hence, important extra-pancreatic actions may be responsible
for the hypoglycemic effects of these compounds, that
is, induced hepatic glycolytic enzymes, impaired insulin sensitivity, increased membrane receptors,
lowered insulin resistance, or other as yet undefined
mechanisms.
Phenformin, a biguanide, is metabolized to some
extent by the liver, but approximately 65% may be
excreted unchanged by the kidneys. The hypoglycemic effect of the "short-acting" tablet lasts six to
eight hours. In contrast, the timed disintegration capsule has a duration of action from 8 to 14 hours
because of prolonged gastrointestinal absorption of
the drug . The mode of action of these agents is not
completely understood. There is evidence that phenformin lowers blood sugar levels by accelerating anerobic glycolysis and delays the absorption of glucose
from the gastrointestinal tract. Phenformin also decreases hepatic gluconeogenesis of diabetic animals,
but this has not been confirmed in man. It is also
quite possible that the anorexigenic effects of this
agent may lower caloric intake, and help exert its
hypoglycemic action in this manner .
Side effects and toxic effects are relatively rare
with the sulfonylureas. Hematologic, hepatic, and
dermatologic reactions have been described. An "antabuse" effect has been noted with chlorpropamide.
Rare cases of hypersensitivity angiitis have been described. Dilutional hyponatremia has been noted
with chlorpropamide, and very occasionally with tolbutamide. In contradistinction, tolazamide and
acetohexamide appear to have a proximal tubular
diuretic effect.
Side effects of phenformin consist primarily of
MCV QUARTERLY 13(1): 24-25 , 1977
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gastrointestinal reactions. Lactic acidosis, however, is
a serious problem, particularly in the phenformintreated diabetic with liver or renal disease, who is
vulnerable to a variety of medical conditions which
may lead to tissue hypoxia, that is, myocardial infarction, peripheral vascular disease with gangrene,
and gastrointestinal bleeding. In addition, alcohol
and phenformin are a particularly dangerous combination.
There are a number of drugs which may interact
and potentiate the effects of the sulfonylurea compounds. These include phenylbutazorie, probenecid,
alcohol, salicylates, and monamine oxidase inhibitors. The list is growing, and the clinician treating
the diabetic with sulfonylureas must be constantly on
the alert.
The indications for oral agent therapy are relative, depending upon the patient's age, weight, fasting
and postprandial blood sugar levels, and intensity of
symptoms. Oral agents have a place in the management of the maturity onset diabetic. The aim of therapy of the diabetic patient is to produce normal
weight for frame and height, to obtain as close to
normal fasting and postprandial blood glucose levels
as possible, to maintain normal lipid levels, and to
keep the patient free from hypoglycemic episodes.
Diet or insulin therapy or both are the bases of treatment for the non-obese patient with fasting bfood
glucose values above 160 mg/ JOO ml. A weight reduction regimen, however, is the mainstay of management
of the obese maturity onset diabetic. This requires
constant dietary counseling by the physician, the
dietici a n, and the nurse-educator. In most cases, if
weight reduction is successful, plasma glucose and
lipid levels will approach normal values, and the patient will usually become asymptomatic. If the plasma
glucose still remains high, and particularly if the patient
is still symptomatic, the sulfonylurea agents may be
tried. If hyperglycemia is not controlled within a short
period of time, by either short- or intermediate-acting
agents, as well as long-acting sulfonylurea compounds, then insulin should be administered; the
"uncontrolled" patient may also have been taking
other drugs during this period which may antagonize
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the action of the oral agents, for example, corticosteroids in pharmacologic doses, excessive doses of thyroid hormones, diuretics which may produce moderate to severe hypokalemia, oral contraceptives, and
nicotinic acid in pharmacologic doses. More significantly, the patient must be warned against increasing
weight gain during the administration of these oral
agents. All these factors must be borne in mind in the
consideration of "secondary failures. " Hypoglycemia
during oral therapy may result from overdosage (that
is, failure to titrate dosage downward), poor choice
of the oral therapeutic agent, omission of meals, renal
or hepatic insufficiency, and interaction with other
drugs, or alcohol.
In conclusion, comment is made on the findings
of the University Group Diabetes Program (UGDP).
The purpose of the UGDP was to determine whether
or not control of blood glucose levels would help to
prevent or delay vascular disease in non-insulin-requiring diabetics. After 8 1/2 years of follow-up at 12
university-affiliated treatment centers, "The findings
of the study indicate that the combination of diet and
tolbutamide therapy is no more effective than diet
alone in prolonging life. Moreover, the findings suggest that tolbutamide and diet may be less effective
than diet alone or diet and insulin, at least insofar as
cardiovascular mortality is concerned." The debate
on the validity of this study still rages . A number of
the criticisms leveled against the study by diabetologists, other clinicians, epidemiologists, and statisticians are discussed. These include inappropriate patient selection and randomization, higher risk factors
at the outset of the study, ma nipulation of electrocardiographic data, risk factors such as smoking
and hypertension not measured or monitored, use of
fixed dosage of drug, clinic preponderance regarding
mortality (it has been alleged that the bulk of tolbutamide mortality occurred in four clinics, Birmingham,
Boston, Cincinnati, and Minneapolis), use of "patient data" against "computerized data," neglect of
appropriate "vascular" history, neglect of "co-morbidity," contradictory clinical studies here and
abroad, and the danger of extrapolation of the
UGDP findings to other sulfonylurea agents.

Diabetes in Children and Adolescents;
Observations on Diabetic Microangiopathy
ELSA PROEHL PAULSEN, M.D.

Associate Professor of Pediatrics, University of Virginia School of Medicine, Charlottesville, Virginia

You may well wonder why I have combined a
talk on diabetes in children and adolescents with one
on diabetic microangiopathy when as pediatricians
we rarely, if ever, see clinical evidence of the seql!elae
of vascular disease in our patients. If we see proteinuria in a child, we seek another cause. We may see
young teen-agers with a microaneurysm or a trace of
protein, but we soon refer them to our internist
friends who fall heir to the care of problems that
doubtless have their beginning in childhood years .
Pediatricians are, therefore, concerned about these
problems an d the adequ acy of treatment they are
prescribing for their young diabetic patients.
There is a recent movement to place considerable emphasis again on strict control of blood glucose as a means of reducing complications of diabetes. In an effort to achieve better control rnany
physicians are placing their patie11ts on two injections
a day.
I believe we can say that there are few, if any,
physici ans today who could duplicate Dr. Elliott P.
Joslin's success in obtaining patient cooperation in
his efforts to control their diabetes. Yet data from his
clinic show that only a small percentage achieved
what he considered excellent control. Nqr did we see
a striking difference in the incidence of complications
in his patients when compared with that in the general diabetic population.
I do not minimize the need for achieving as
nearly optimal control as one can with insulin , but I
believe a return to the old emphasis on strict control

Correspondence and reprint requests to Dr. Elsa P. Paulsen ,
University of Virginia School of Medicine, Charlottesville, Virginia 2290 I.
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does a disservice to our diabetic children and adolescents . It misleads them into thinking that controlling
the blood sugar adequately is possible with present
day methods of insulin administration; that if this is
achieved, it will prevent or slow down complications;
and that if this is not achieved, even with the most
conscientious efforts, it is the patient's fault. I believe
there is evidence that none of the above is true. A )so,
this re-emphasis on <;.:ontrol and what it does or does
not do to the basement membrane, diverts our attention from pursuing other productive avenues of research that may uncover clues and therapeutic approaches. It is with some of these avenues that I
would like to acquaint you and stir your interest.
I would like first to address myself to important
considerations in the care of the child or adolescent
who has diabetes .
It is , of course, fundamental that the patient and
the parents be properly educated about diabetes and
its control at the very beginning if one is to expect
acceptance and participation in a program of good
management. We feel this should always be initiated
on a hospital ward even if the child is not acidotic.
Here the patient and parents can work with a teaching team in a relaxed setting where questions can
readily be answered before the family is left on its
own. The focus of instruction for the very young
child and infant is both parents; by 7 to 10 years of
age the child can help with urine testing; the 11-yearold can learn to give his or her own injections. In the
teens the patient becomes the focus of instruction
with parents also learning the facts and techniques.
Do not be misled on this point: teen-agers very much
need and want the support of their parents in these
circurnstances.
As soon as the patient has intravenous feedings
MCV QUARTERLY 13( 1): 26-30, 1977
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discontinued and is ambulatory the routine that he or
she will continue at home is initiated. After the acidosis is cleared the patient is not awakened during the
night hours for either urine testing or supplemental
insulin.
The educational process continues upon discharge from the hospital, first with phone calls to talk
over changes in insulin dosage, and then in weekly
visits to the clinic. As confidence and understanding
increase, visits are less frequent but are continued
with regularity.
What do we teach our patients about diabetes
and how it should be managed?
Good management of the diabetic begins with
the physician's smooth management of the initial ketoacidotic episode, for actions speak louder than
words. I believe pediatricians have an advantage here
because it can be said with certainty, if not with
modesty, that pediatricians have been in the forefront
in the proper administration of fluids and electrolytes.
One need only recall the names of Gamble, Butler,
and Darrow to know that we have had good mentors.
Fluids play a most important role in recovery from
acidosis; no amount of insulin will rid the patient of
the accumulation of hydrogen ion and restore his or
her base deficit. Briefly, the initial hydrating solution
is a mildly hypotonic solution of sodium chloride free
of potassium, containing bicarbonate if acidosis warrants its use. This is followed by a more hypotonic
solution including potassium and dextrose, usually
around the second hour. We discourage the use of
isotonic saline as unphysiologic because of its high
anion concentration and the absence of free water.
Pediatricians also for many years have been administering small doses of insulin at frequent intervals
instead of the large doses prescribed in adults. Indeed, the recent introduction of continuous intravenous administration of low levels of insulin has
little if any advantage over our long-used methods of
administration. We begin with 0.5 to 1.0 units/ kg
crystalline insulin, giving half intravenously and half
deep subcutaneously, Every hour the dose is reduced
by 50% unless the interval reveals no progress in
reducing the blood glucose. The previous hour' s dose
is then repeated.
After intravenous therapy is discontinued and
oral feedings initiated, regular insulin is given with
meals for one or two days. Lente®, a long-acting
insulin, comprised of 70% Ultralente® and of 30%
Semilente®, is then given once daily prior to breakfast.
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Our goal is to allow a trace or 1 + glycosuria in
urines tested prior to meals and at bedtime. The
Lente® is increased daily by 2 to 4 units until control
is achieved.
We teach the patient to monitor his or her diabetic control through daily urine tests: that is, a
double-voided specimen before breakfast, before supper, and at bedtime. After discharge from the hospital we allow time for a pattern to develop in response
to the child's home and school routine. If the glycosuria falls to negative levels after discharge as so
frequently happens, the patient reduces the Lente®
Insulin by 2 units after a day of negative tests, or by 4
units if there are symptoms as well. If glycosuria
increases uniformly before breakfast and before supper, the patient increases it by 2 units every three to
four days until control is again achieved. If a pattern
of glycosuria develops in which all the morning
urines are 3 + to 4 + and the pre-supper urines are 0
to 1+, the patient increases the Ultralente® or longacting portion of the Lente® mixture. Conversely, if
late afternoon urines are high in sugar, the patient
increases the short-acting or Semilente® portion. In
this way we achieve as good control over the 24-hour
period as with those who use NPH® twice a day and
avoid the use of two injections. For this reason we
have abandoned the use of NPH® in favor of the
Lentes®. As those of you who follow young children
know very well, there frequently is no pattern to the
glycosuria, and levels will go from negative to 4+ .
One may be guided in such circumstances by daily
urine volumes and adjust the insulin to keep urine
volumes in the normal range.
If acetone appears, the patient is to take regular
insulin at that time. He or she is asked to take 1/ 5 of
his or her daily dose of Lente® for moderate or large
and 1/ 10 for small amounts of acetone. This is repeated at subsequent testings if acetone persists.
If the child becomes ill and is unable to eat or is
vomiting, the Lente® is omitted and small amounts of
regular insulin are given. Depending on the nature of
the problem, the child will be seen in the Emergency
Room; admitted, or followed at home by phone instructions.
The diet we propose for the diabetic is no different from one we propose for the non-diabetic. It consists of a good source of protein as the cornerstone of
the diet, carbohydrate obtained mainly from
starches, a drastic reduction in refined sweets, a mixture of predominantly unsaturated and saturated
fats, and, finally, foods containing adequate rough-
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age, minerals, and vitamins. We allow the patient to
use his appetite as his guide, warning against gorging
or excessive snacks, and to use his weight-for-height
gains as a monitor of his progress. If overweight is or
becomes a problem in the diabetic, he should be
approached as a youngster, not a diabetic, with a
weight problem. I see no reason to single out the
diabetic in his diet therapy when there is no scientific
data to suggest this approach is any more harmful to
him than to his non-diabetic peers.
We do not attempt to make gross changes in a
patient's lifestyle. We recommend regular exercise for
all youngsters, but we do not urge all-out vigorous
athletics if that is not the child's habit. If exercise can
be anticipated, the morning dose of insulin is reduced. If it cannot, increased carbohydrate intake
during and after the exercise is required. We explain
to teen-agers the serious effects of smoking on the
cardiovascular system and urge them not to begin.
We explain the hazards of drinking and urge care in
this area if they do indulge.
There are a number of special problems we see in
children and adolescents.
First of all, the term "brittle" diabetic is frequently used to describe the majority of juvenile diabetics. I believe this is too broad a use of the term and
often reflects only a poor understanding of how to
manage youngsters whose exercise pattern is unpredictable and whose increased needs with growth are
not properly met. I would reserve the term for the
juvenile diabetic who is truly difficult to manage; in
my experience such patients are few in number and
all have been teen-age girls under severe emotional
stress.
In the adolescent years there is both an increase
in need for insulin and an increase in binding, with
insulin resistance of variable degree resulting. Requirements can often rise at an alarming rate to needs
of 140 to 160 units per day. The periods of increased
need are variable and unpredictable in their length .
When the total daily dose reaches 90 to 100 units the
dosage is split; 2/ 3 is given before breakfast and 1/ 3
before supper. It is frequently advisable to admit the
patient to make these adjustments. We admit the
teen-ager to the Children's Rehabilitation Center
where both physical and school activities can be pursued so that home conditions are more nearly simulated than on a hospital ward. A schedule is set up in
which, again, the patient participates. Pre-meal and
two-hour post-meal blood glucoses are obtained,
urine volumes are measured, and caloric estimates of

the food intake that satisfies the patient's appetite in a
normal manner are made. Urine volumes are collected in the following manner: patient voids and
discards at 7 AM ; Urine #1 is voidings up to lunch;
urine #2 up to dinner; urine #3 up to 9 PM, and urine
#4 overnite to 7 AM. In this manner grams of glucose/ hour spilled in respect to a meal can be 1:,;alculated. Urine volumes collected periodically at home
give the diabetic another index of his control.
True insulin resistance is defined rather arbitrarily as a requirement that exceeds 200 units per
day, occurring in the absence of ketosis, infections, or
other known stresses. The few cases that have occurred in juvenile diabetics have been predominantly
among teen-agers 14 to 16 years of age. Most are due
to increased antibody formation and respond either
to changing to pork insulin, which is less antigenic
than beef, or to steroid therapy . We have recently
reported the very rare occurrence of severe resistance
to insulin in a 17-year-old gi'rl who does not have
excessive antibodies either to insulin or to her insulin
receptors and showed no improvement on steroids.'
She was resistant to as much as 5,000 units in pork
regular insulin given subcutaneously, but responded
normally to a continuous 24-hour infusion of insulin
and was well regulated in 60 to 70 units pet day. After
5 months of continuous I. V. insulin she remitted
spontaneously and is presently regulated on 85 units
Lente® in the morning and 35 units Lente® before
supper. Since our report, 5 more females of similar
age with the same problem have come to our attention.
Over-treatment with insulin can of course result
in hypoglycemia, but it can a lso result in a curious
and unexplained phenomenon called the Somogyi
reaction, which usually appears after sudden and excessive increases in insulin. The reaction is characterized by polydipsia and polyuria, sometimes to an
overwhelming degree. Unlike the patient in acidosis,
however, the C0 2 is not elevated though the glucose
values may be very high. The explanation given by
Somogyi is that the intense hypoglycemia generated
by excessive insulin, usually occurring between 2 AM
and 4 AM, causes a discharge of adrenalin and a swift
rise in blood glucose to excessive levels. The increased
glycosuria in the morning and the excessive polyuria
suggest the need for more insulin, and a vicious circle
ensues. The patient needs to be hospitalized, taken
off long-acting insulin, and regulated on regular insulin before returning to Lente®.
One final problem we encounter, especially in
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teen-agers, is noncompliance. This must be dealt with
in a sympathetic yet firm manner. One can only have
deep feelings of empathy for youths who are struggling to establish their own identity in a world generally hostile to teen-agers, and who are aware that in
the not-too-distant future they will be on their own.
Our approach, 2 therefore, is to keep the demands on the patient simple but to work closely with
him to follow these simple rules:
1) Double void urine twice a day, test for glucose and acetone, and record results so they
can be reviewed with the patient.
2) Take insulin without fail each morning.
3) Eat a sound diet at regular time intervals and
in amounts that satisfy appetite and maintain
normal weight.
4) Keep regular medical appointments at 3month intervals. This provides an opportunity to review the patient's understanding of
diabetes and its control.
would now like to turn to a discussion of
abnormalities in serum proteins, platelets, and red
blood cells of diabetic subjects discussed at a conference on Diabetic Microangiopathy held by the Kroc
Foundation in April, 1976. The conference was arranged by Dr. Donald McMillan of the Sansum
Medical Research Foundation and Dr. John Ditzel
of Aalborg, Denmark, and the papers have appeared
in the November, 1976 supplement of Diabetes. 3
The abnormalities I wish to describe may play a
role in the genesis of diabetic angiopathy or are factors that reduce tissue delivery of oxygen by hemoglobin. These mechanisms can lead to tissue hypoxia
and subsequent tissue damage.
First, Dr. McMillan, 4 as well as others, describes
significant increases in serum proteins in diabetics.
No system of proteins is spared. Studies of newly
diagnosed diabetics show increases as great as those
in established diabetics. Abnormalities are independent of the presence of sequelae of microangiopathy .
The majority of the proteins elevated in diabetics
are acute phase reactants: a 1 acid glycoproteins, °'1
antitrypsin, haptoglobin, ceruloplasmin, C-reactive
protein, C3C, C4 and C3 activator, and fibrinogen.
Albumin levels are lower than normal. By direct measurement Dr. McMillan has shown that diabetic serum has a greatly increased viscosity which is due to
the elevation of these proteins. The abnormal viscosity bears no relation to age, sex, body weight or
duration or type of treatment of the diabetes.
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Erythrocyte aggregation is markedly increased
due to the increased fibrinogen level as well as to
increases in other elongated proteins. Increased
erythrocyte aggregation has the added effect of enhancing the coagulation of blood.
Platelet aggregation is also increased in diabetics
in the early stages of the disease as well as later. There
is a greater sensitivity than normal to aggregating
agents such as adenosine diphosphate (ADP), epinephrine, and collagen.
At the same time that intravascular factors are
leading to the occlusion of small blood vessels, the
fibrinolytic system, the body's defense against vascular occlusion, is decreased. This abnormality is more
pronounced m patients with signs of microangiopathy.
We have recently made observations on red cell
membranes in diabetics and have noted an abnormal
adherence of hemoglobin to the red cell membranes. 5
Red cell ghosts prepared by the method of
Dodge were solubilized in 1% sodium dodecycl sulfate (SOS), separated by gel electrophoresis and
stained with Coomassie® Blue (Figure). Increased
amounts of hemoglobin were noted in the membranes of diabetics, B, C, and D, compared to those
of a non-diabetic child, A. Dislodging the hemoglobin from red cell ghosts with Tris (hydroxymethyl
aminomethane ), a nonionic buffer, simultaneously
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Figure-Membrane proteins of erythrocyte ghosts in I% SDS separated by polyacrylamide gel electrophoresis and stained with Coomassie"9 Blue. A to D (untreated ghosts): A, normal 12-year-old; B,
8-year-old on insulin one month; C, top layer of ghosts, pale yellow,
D, bottom layer, pink, 15-year-old on insulin five years. E and F
(ghosts extracted with 0.01 M Tris, pH 8.2): E ~A; F ~ B.G to J
(Tris eluates): G ~ A, H ~ C, I ~ D, and J ~ B. In D note the
doublet of band 6 and the heavy band of hemoglobin, and the
appearance of those components in the Tris eluate. The proteins
are eluated roughly in proportion to the amount of hemoglobin
adhering to the membrane.
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removed both peripheral and integral membrane proteins. E and F represent the ghosts after membrane
bands 4.1 to 4.5, 5, 6, and 7, as well as the hemoglobin. It is suggested that the tightly adhering and
increased amounts of hemoglobin on diabetic membranes interfere with normal erythrocyte deformability because deformability is influenced by the peripheral proteins of the inner aspect of the red cell
membrane.Normal deformability is essential for normal blood flow since the diameter of erythrocytes is
greater than the diameter of the smallest blood vessels through which they must pass.
Finally there is evidence of disturbance in oxygen transport in diabetics. Rahbar 6 originally described the abnormal increases of the minor hemoglobin components Ala, b, and c in diabetic adults.
We have made a similar report in children. In spite of
acceptable control of their diabetes, young children,
and adults as well, have levels that are twice normal.
The important fact about hemoglobin Ale is that it
does not react with 2, 3 diphosphoglycerate (2,3
DPG), thus reducing the ability of hemoglobin Ale
to yield oxygen to the tissues. Opposing this impairment of oxygen release due to increased levels of Ale,
Ditzel has found elevated levels of 2,3 DPG but a
lower than normal P 50 • Phosphate administration to
these diabetic children brought their P50 to the level of
the normal control group. This may be a therapeutic
approach toward improving oxygenation of diabetic
tissue that warrants further study. 0
The legitimate question can now be raised as to
whether these intra vascular abnormalities are not due
solely to insulin ·deficiency and therefore simply reflect inadequate control of the diabetic state with
insulin. This may be true. At present we do not know.
However, in respect to the increases in acute phase
proteins observed in diabetics, studies of protein synthesis of the perfused rat liver by Miller have revealed
a very interesting finding. 7 Abnormal alpha cell function is an integral part of the diabetic state. 8 Glucagon secretion continues during periods of glucose
plenty and is stimulated by amino acids in the pressure of hyperglycemia. Miller has found that glucagon, either alone or in combination with cortisol,
stimulates the acute phase proteins including fibrinogen. The in vitro effects can be abolished with insulin.

The possibility thus arises that glucagon excess in a
setting of insulin deficiency is the initiating factor of
the sequence of events leading to microvascular occlusion. We have begun a prospective study in our
young diabetics of the degree of abnormality of
glucagon secretion and its progression, and the levels
of acute phase proteins, to determine if a correlation
exists between them.
I conclude by paraphrasing a well-known slogan, "We want to find a cure for diabetic microangiopathy before our diabetic children leave adolescence," because success of treatment undoubtedly lies
in applying it in the trouble-free childhood years.

The figure is reproduced with permission from Diabetes (25:

805-930,. 1976).
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Introduction.
Elevated titers of natural antibodies have been
demonstrated in the sera of patients following transplantation.1 - 6 These humoral responses were thought
to be associated with rejection .1 - 10 This concept was
challenged by investigators whose studies associated
these responses with infection or with injection of
heterologous serum. 11 - 15 Nevertheless, the possible
prognostic significance of these relatively simple tests
has continued to evoke interest.
This study was undertaken to compare the humoral responses in three different groups of patients
with organ transplants in order to evaluate the influence of duration of the homograft and the attendant immunosuppression.
Materials and Methods.

Patient Selection.
Fifty-eight patients who had received homografts were selected for study. The patients were divided into three groups: Group 1, 20 patients tested
prior to transplantation and in the immediate posttransplant period with a mean duration of follow-up
of 3.3 months; Group 2, 19 p~tients tested approximately five to seven years following transplantation
with a mean follow-up duration of 82.2 months; and
Group 3, 19 patients tested approximately ten years
following transplantation with a mea n follow-up duration of 118.1 months.

Correspondence and reprint requests to Dr. Marion Waller,
Box 263 , Medical College o f Virginia, Richmond , Virginia 23298.
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Tests for Anti-Rat Erythrocyte Antibodies ( Heterophil Antibodies).
Rat erythrocytes were washed three times in saline and reconstituted to a 2% suspension. The test
sera were tested at a 1: 20 dilution and in serial twofold dilution for antibody titer. The tubes were allowed to stand at room temperature for 30 mintues,
spun for 1 minute at 77 g, and read with the naked
eye.

Tests for Rheumatoid Factor (A nti-Fc IgG antiglobulins ).
The sensitized human cell test (SHC) was used.
A selected DCe/ DCe test cell was sensitized with
Ripley serum (highctitered antiDC) diluted 1: 10. The
Rh-positive cells were sensitized for 60 minutes at 37
C and then washed three times in sa line. Test sera
were titrated in saline in 0.1 ml volumes. Titers of
1: 20 or above were considered positive.

Tests for Chymotrypsin Agglutinators ( Anti-Fab
IgG Antiglobulins) Hydrolysis of IgG globulins.
The IgG globulins of anti-Rh serum (Ripley)
were isolated by (N H4)2S04 precipitation followed by
chromatography on diethylaminoethyl (DEAE)-cellulose as previously described . 16 Methods of hydrolysis of the IgG globulins with chymotrypsin have
been reported. 17

Sensitizations. One milliliter (containing 5 mg of
digested globulin) was added to 0.1 ml of hum an 0,
DCe/ DCe washed packed cells and sensitized at 37 C
for one hour. T)le sensitized cells were washed three
times with sa line and reconstituted to a 2% suspension. The cells were tested with goat anti-Fe and antiFab (Hyland Laboratories, Los Angeles, California)
antisera.
M C V QUARTERLY 13(1 ): 32-36, 1977
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Methods of testing. Tests for serum agglutinators
were performed in tubes by adding 0 . 1 ml aliquots of
the sensitized cells to an equal volume of undiluted
and serial twofold dilutions of sera to be tested. The
mixture was allowed to stand at room temperature
for ten minutes, and then spun for one minute at 77 g
and read with the naked eye.
Erythrocyte Sedimentation Rate ( ESR).
The Westergren method was used to document
the ESR. The fall of the erythrocytes in millimeters in
one hour was noted . The normal sedimentation rate
with this method is 0 to 15 mm for men with an
average of 4 mm, and 0 to 20 mm for women with an
average of 5 mm.

Nitroblue-Tetrazolium Test ( NBT) .
The NBT test was performed according to the
modified method of Dorwick' 8 on venous blood collected in 4.5 ml vacutainers containing 3.8% sodium
citrate. The NBT test was performed as soon as possible after the blood was drawn in order to eliminate
morphological changes caused by prolonged exposure to the anticoagulant.
A standard so lution of 0.4% N BT was prepared
in a IO ml stoppered volumetric flask by dissolving 20
mg of nitroblue tetrazolium (Grade Ill reagent,
N6876, Sigma Chemical Co., St. Louis, Missouri) in
5 ml of sterile 0.85% isotonic saline. To dissolve the
NBT, the stoppered flask was swirled under hot, running tap water until the solution beca me clear. This
solution was then filtered and transferred to a brown
bottle and stored at 4°C. The solution was stable for
72 hours .
Citrated blood, 0.2 ml, was placed in a test tube
and 0.1 ml of 0.4% NBT was added. The tube was
mixed by gently shaking, capped and incuba ted in a
water bath at 37 C for 30 minutes . The tube was
removed from the water bath, and one drop of the
blood-NBT test mixture was added to two precleaned, la beled glass slides. Special care was taken to
avoid damage to the white blood cells. The slides
were air-dried and stained with Wright's stain. The
stained slides were examined microscopica lly using
an oil immersion lens and 100 neutrophils were
counted. Neutrophils were classified as "NBT-positive" if they contained any visible formazan deposits .
Cells that were disrupted or clumped together were
not counted . The percent of N BT-positive neutrophils was reported as 0% to 15% normal and 16% to
I 00% normal.

Serum Electrophoresis.
Serum electrophoresis was performed on cellulose acetate strips, using the Microzone cell, Model
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R-101 (Beckman Instruments , Inc., Fullerton, California).
Results.
Figure I shows the humoral responses of the 20
patients in Group I during the first five to six months
following transplantation. The anti-Fab antiglobulins are design ated by dark circles. These antibodies
a re usually produced as lgG globulins. Only 7 of the
20 patients showed titers at any time in excess of the
pretransplant values. Titers below I: 20 are shown as
lines without a dot dipping below the I: 20 titer level.
Fluctuations in titer are common.
The anti -rat erythrocyte antibodies are designated by open circles. These antibodies are almost
a lways produced as lgM globulins. Fifty percent (10
out of 20) of the pa tients showed titers in the posttransplant period higher than the pretransplant titer.
Once again, fluctuations in titer are common. There

I
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40
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Fig I-Titers of anti-rat erythrocyte a ntibodi es and chym otrypsin
agg lutin ators in 20 patients in the immediate post-transplant period. Open circle: anti-rat erythrocyte: Dark circle: chymotrypsin
agglut in ato rs.
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is a tendency for both antibodies to return toward
pretransplant levels 9 to 12 months after transplantation.
Although 4 of these 20 patients gave positive
tests for rheumatoid factors, on ly 3 (patients 2, 7 and
13) showed titers in excess of the pretransplant values. Titers were not constant, as is observed in
chronic rheumatoid arthritis, but fluctuated, cresting
and then falling, like the other antibodies. The rheumatoid factors were invariably made as IgM globulins.
Modestly elevated titers of anti-sheep erythrocyte antibodies (I : 80) were found in only 2 (patients 3 and 11) of the 20 patients.
The blood groups of the 58 patients did not
significantly influence the serological responses of the
antibodies tested .
Figure 2 shows the titers of the anti-rat erythrocyte antibodies (lgM globulins) and the anti-Fab
antiglobulins (IgG globulins) in the three groups of
patients in order of increasing duration of the homograft and attendant immunosuppression. The titers of
the antibodies in Group I were read at three months
post-transplant. The titers of Groups 2 and 3 were
performed when they appeared for post-transplant
check-up. It is apparent from Figure 2 that the number of patients with significant titers of antibodies
decreases with duration of the homograft.
Three of the 38 long-term homograft recipients
(five to ten years) had positive tests for rheumatoid
factors . Neither the presence nor the titers of the
rheumatoid factors were related to the duration of
the graft. One patient who had shown high titers of
rheumatoid factors in the past lost this activity 11
years post-transplant. This patient has developed reticulum cell sarcoma.

Anti - rot erythrocyte
antibody

Antibody Titers

320
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66
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TABLE I
a) Relationship of level of gamma globulins to
/gG antibody production as chymotrypsin agglutinator
< 12%

> 12%

Tota l

5/ 6
2/ 11
0/ 6

9/ 14
3/ 8
5/ 13

14/ 20(70%)
5/ 19 (26% )
5/ 19 (26% )

66

b) Relationship of level of gamma globulins to
lg M antibody production as anti-rat antibody

6

•••
•
••
••••
••••
••••

Electrophoretic patterns of tlie serum proteins
were performed on the three groups of patients. The
patients were divided into two groups, those with
gamma globu lins below 12% and those with gamma
globulins above 12% (Table I) . In Group I, 5 out of
the 6 patients with gamma globulin levels below 12%
made anti-Fab IgG antibodies as did 9 out of the 14
with gamma globulin levels above 12%. Thus, 70% of
Group I made these antibodies. However, in Group
2, on ly 2 out of 11 made these antibodies when the
level of gamma g lobu lin was below 12%, while 3 out
of 8 made them when the level of gamma globulin
was above 12%. In the whole group, 26% made these
antibodies. In Group 3, none of the 6 patients with
gamma globulin levels below 12% made these IgG
antibodies, whi le 5 of the 13 with gamma g lobu lin
levels above 12% did so.
A similar pattern is seen for the IgM an ti-rat
erythrocyte antibodies. There appears to be no effect
of low levels of gamma globulin in the immediate
post-transplant group (Group I), but in the longterm patients, the influence of low levels of gamma
globulin on both the lgG and lgM antibodies is demonstrable.
Table 2 shows the relationship between the serum creatinine levels and the failure to show humoral
responses in 37 of the long-term transplant recipients .
Among the 12 patients with elevated levels of creatinine, the incidence of both IgG and IgM antibodies is
decreased. This decrease in antibody production was

Group 1*
Group 2**
Group 3***

6

t::.t::.t::.t::.

666

chymotryp s1n
oggluti notors

Relationship of level of gamma globulin to the
production of humoral antibody.

D
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ODDO

OD DO
DODO
ODDO

66
t::.t::.t::.t::.

666 6

66

66D.6

••
•••
••
••••
••••
••••

DD
DOD
DD
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BBBB

Fig 2-lnfluence of duration .of homograft and attendant immunosuppression on humoral antibodies in 58 patients. Triangle: mean
3.3 months: Dark square: mean 82.2 months: Open square: 118.1
month s.

Group 1*
Group 2**
Group 3***

< 12%

> 12%

Total

6/ 6

10/ 14
3/ 8
6/ 13

16/ 20 (80% )
5/ 19 (26%)
7 / 19 (37%)

2/ 11
1/ 6

* Mean 3.3 months
•• Mean 82.2 months
*** Mean 118. I months
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TABLE 2
Thirty-seven patients with long-term homografts showing a relationship between the serum creatinine level and failure to show humoral responses
lgM Antibody Responses
(anti-rat erythrocyte antibody)
Creatinine levels:

3.1 and above

0/ 3

2.1-2.5
0/ 2

2.6-3.0
0/ 1

1.5-2.0
1/ 6

0.9-1.4
11 / 25

1.5-2.0
0/ 6

0.9-1.4
I 0/ 25

lgG Antibody Responses
(chymotrypsin agglutinators)
Creatinine levels:

3.1 and above

0/ 3

2.7-3.0
0/ 1

not related to a significantly higher dose of maintenance immunosuppression .
Since infection plays a prominent role in patients
maintained for long periods on immunosuppressive
agents, the erythrocyte sedimentation rate and the
NBT test were performed on 37 of the 38 patients in
Group 2 and 3. The erythrocyte sedimentation test
was abnormal in 24 of the 37 patients ( 65% ). The
numerous factors affecting this test, such as anemia
and dysglobulinemia, lessen the value of this test for
evaluation of patients with positive tests. The NBT
test was only positive in 3 of the 37 long-term patients. Careful review of the discharge summaries
corresponding to the period at which the test was
done failed to reveal a reason for these abnormal
tests. In a further effort to evaluate the significance of
these positive tests, C3 and C4 levels were determined
on these patients' sera along with 12 other patients
who did not show positive NBT tests. The levels of
C3 and C4 were not significantly altered in the patients with positive NBT tests.
Discussion.
These studies document humoral antibody activity in the immediate post-transplant period. Rises in
titer of both IgG antibodies (anti-Fab lgG antiglobulins) and lgM antibodies (anti-rat erythrocyte antibodies) are demonstrable. The antibody rises are usually inverse to each other, implying that different
antigens elicit these responses. The antigens on the
rat erythrocyte are also found on dog and rabbit
erythrocytes, and related antigens are present on human B erythrocytes. Thus, the antibodies are termed
heterophils . McDonald and co-workers 19 recently
studied these antibodies and related the absence of
the "rat" antigen (HT-A) in the recipients to increased rejection of kidneys from donors with the
antigen . Their studies have clinical importance and
help to define complex tissue antigens which will
receive more attention in the future.
Rises in titer of the anti-Fab lgG antiglobulins

2.1-2.5
0/ 2

could not be closely associated with rejection. These
antiglobulins are associated with severe suppurative
infection in a hospitalized population. 16 In posttransplant patients, there is a tendency for these antiglobulins to rise when the titers of the anti-rat erythrocyte antibodies are falling, 14 which suggests that
these are auxiliary immune responses or responses to
antibody-antigen complexes.
The dramatic serological responses in the immediate post-transplant period are not repeated in subsequent years. This is probably due to immunosuppressivt: therapy. However, we observed no inhibition
of polymorphonuclear phagocytosis nor depression
of C3 or C4 levels. On the other hand, laboratory
tests for infection (sedimentation rate, NBT test) may
react non specifically, making the diagnosis of occult
infection difficult.
As all those interested in transplantation know,
the greatest drawback in currently available methods
of immunosuppression is their nonspecificity. This
fact has stimulated interest in immunological enhancement of the kidney graft. Evidence exists that
kidney grafts in rats can survive by virtue of enhancement.20-25 One approach in humans entailed the production of immune sera to leukocyte antigens, followed by the hydrolysis of the antibody to remove the
complement-fixing Fe fragment. The resulting Fab
fragments were injected into the recipient to bind to
the antigenic sites on the graft. 26 As discussed previously, the serum agglutinators are antiglobulins
which have specificity for Fab fragments following
hydrolysis. These antiglobulins are naturally occurring IgG globulins commonly found in low titer.
However, the serum agglutinators (named homoreactant in rabbits) are not apparently stimulated by the
injection of Fab fragments, 27 but once stimulated,
their ability to reconstitute the biological potential of
the Fab fragment has been established. 28 Therefore, it
would be essential to test the recipient for these antiglobulins prior to the injection of the Fab fragments .
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In any case, the role of the anti-Fab antiglobulins
must be considered when Fab fragments are used to
achieve blocking of the antigenic sites of a homograft.
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BOOK REVIEW
Marks, Geoffrey and Beatty, William K. Epidemics.
New York, Scribner's, xii, 323, illus. 1976. $9.95.
McNeil!, William H. Plagues and Peoples. Garden
City, New York, Doubleday, viii, 369, 1976. $10.00.

Epidemics, like the poor, a re always with us; the
rapid rise a nd the equally rapid fall of swine influenza
attest this statement. The publication of two books
with the common theme of epidemic disease, but with
different approaches to it , is therefore welcome and
timely, particularly as there are no authoritative
books on this subject in print.
Both book s rely on established secon d a ry
so urces an d especially on one nineteenth century
monument of sc holarship: August H irsch 's Handbook of Geographical and Historical Pathology'; both
books describe the chronology of epidemic disease on
a worldwide bas is ; both book s a re primarily written
for th e lay m a n; and both books contain extensive
reference notes. Where they differ is in their correlation of infectious disease and social history. This , of
course, is not surprising as Messrs. Marks and Beatty
are a medica l journalist and medica l bibliographer
respectivel y, while Dr. McNeil! is a social hi storian.
Epidemics presents a broad view of the worldwide pattern of infectious disease, ranging from biblical plagues to recent influen za pandemics. There is no
ac knowledgement of medical consultation in the
preface, and this may acco unt for some of the book 's
shortcomings, one of which is the absence of comment on the secular changes in the virulence of
st reptococcal infections . The mo st glaring omission is
rubella , both as an infectious di sease and as the cause
of birth defects. Rubell a would have been an ideal
foundation on which to build the last chapter of the
book, entitled "The Continuing Scene, " which attempts to "provide bridges" between the old and the
new epidemiology. One "bridge" used-"Dog Bites:
An Unrecognized Epidemic"-is somewhat specious;
another, lead poisoning , lacks bibliographical support, ignoring both the Baltimore epidemic of 1932
(probably the best example of a modern epidemic of
plumbism 2 ) and the possible role of lead poisoning in
the fall of Rome. 3 There is a lso in this chapter a
MCV QUARTERLY 13( 1): 37-39, 1977

misundersta nding of today's epidemiological approach to the chronic non-infectious diseases , for
example, "The term epidemic is currently used
loosely in such statements as 'we a re faced with an
epidemic of heart disease ... '" As Morris has so
frequently pointed out, there is indeed a modern epidemic of heart disease, to which m ay be added lung
cancer and m a ny more syndromes; in fact, modern
epidemiological research into chronic disease control
is a direct extension of the methods used in epidemic
infectious disease investigations.4
Two points of historical interest are missed or
confused. First, the Black Assizes in England in the
sixteent h and seventeenth centuries were six in number , the most dramatic by far being at the old Bailey
in London , where the Lord Mayor of London was
infected with, an d later died from , typhus .5 Second ,
the account of John Snow's cl assic investigation of
cholera in Soho is misrepresented , perhaps because it
is based on a secondary source paper in Scientific
American instead of the readily avai lable original
work by Snow. 6 The famous Broad Street Pump epidemic occurred in 1854, and not in 1849, the year in
which Snow fir st published his theory of cholera
propagatio n. Although Messrs . Mark s's and Beatty's
acco unt does not categorically state th a t the epidemic
occurred in 1849, neither does it make it clear that it
occurred in 1854; surprisingly , this confusion has appeared several times in epidemiological papers during
the past ten years, most nota bly in the first edition of
MacM ahon' s Epidemiology (the date was corrected
to 1854 in the second edition). 7 These are, however,
minor omissions and the book on the whole is acc urate and read a ble, as one would expect from its a uthors' credentials. There is a lingering impression that
Epidemics was written from a previously compiled list
of references rather th a n from primary observations
which were verified and a dded to as the book was
written. This must be a fairly common ploy of writing
in these "publish or perish" days, the references being
used as the point of depa rture rather than the text
an d context of the paper.
In summary, Epidemics serves its purpose as an
interesting, mostly dependable , account of the evolution and ravages of epidemic infectious disease, with
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the authors' comments liberally supported by quotations from contemporary documents. Its content is
mainly descriptive, although it does not entirely ignore the social consequences of disease outbreaks.
Plagues and Peoples is a more scholarly work,
which one would expect from Dr. McNeill, who won
the National Book Award for History in 1964 with
his book, The Rise of the West: A History of the
Human Community. 8 Dr. McNeill's book documents
and explains the effect of epidemic disease on the
structure and evolution of civilization, both through
the microcosm of microorganisms and the macrocosm of man's military machinations. The theme of
war and disease has been dealt with before by Prinzing9 and Major, 10 but neither of their works presents
the correlation of epidemics and social change which
is the basis of Plagues and Peoples. Unlike Messrs.
Marks and Beatty, Dr. McNeill consulted physicians
and medical historians in writing his book, and his
accurate medical facts are supported by 55 pages of
references and notes. Perhaps a brief description of
Pavlovsky's work in landscape epidemiology 11 would
have been welcome in the final pages of the book,
particularly as it is the antithesis of the Australian
experience with myxomatosis, a topic used several
times to illustrate man's ecological blunders. As in all
works of this type, speculation on early epidemics is
replaced by the increasing certainty of documentation and diagnoses after the Black Death; this makes
the later epidemics more vivid and interesting to the
reader, and of more value to the interpreting social
historian.
Neither book contains references to several classical epidemiological texts which should not be ignored in any survey of epidemic disease; the works of
Murchison 5 and Drake 12 particularly come to mind.
It is surprising, too, to see no reference to America's
greatest work on cholera, usually ascribed, wrongly,
to Woodworth . 13 The modern works of Ackerknecht14 and Henschen 15 might have been mentioned, as might the specialized studies of Bell'6 and
Ashburn. 17 The social aspects of disease summarized
in Zinsser 18 could also have received more recognition, and Hare's Pomp and Pestilence' 9 might have
been noted as an introduction to the theme of Plagues
and Peoples. Finally, any work describing the world
picture of epidemics should contain maps to facilitate
the reader's understanding of the geographical and
temporal spread of disease; the only map in either
volume is one on the Black Death in Dr. McNeill's
book. The recent resurgence of interest in medical
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geography might have been used and some of the
many maps in existence copied or modified, if new
maps were too costly to prepare. 20 A good example of
the use of maps to supplement the text is Siegfried's
Germs and ldeas, 21 in itself a pioneering precursor of
Plagues and Peoples.
These two books complement each other; the
descriptive content of Epidemics is expanded in
Plagues and Peoples into a fascinating portrait of the
interaction of civilization and disease, a subject already dealt with by Sigerist. 22 What McNeill has done
for communities needs to be done for individuals,
although a book by L'Etang23 has taken the first
step towards relating disease to the decisions affecting
history made by a single man or woman. Should this
study be made, one could not wish for a more scholarly work than Plagues and Peoples, presented perhaps in the familiar style of Epidemics.
F.J.S.
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A service to medical education from A. H. Robins:
Excerpted from Volume 2

oflheG.I.

Senes

on physical examination
of the abdomen:

Normally palpable organs:
the edge of the li)(er descending ,
on inspiration, below the costal
margin (AJ ; the lower pole of the
right kidney (BJ; the abdominal
aorta (CJ; the descending colon
and the sigmoid ( DJ; the ascending colon (EJ; and occasionally
the bladder (though rising of
this orga n beyond the pubis
does not necessarily indicate
disease).
Impossible to outline, unless
diseased, d istended or enlarged :
the gallbladder, pancreas,
stomach, small intestine, transverse colon and spleen.
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The A H Robins G I Seri es consists of six book- 1
lets, designed to provide a quick, yet comprehen- I
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1
sive review of basic procedures and practices 1n
\
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physical examination as perform ed 1n the office or \ . ,
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at bedside. If you h ave teaching respons1b1llt1es,
limited quantities are available: Part 1 - Inspection,
·--...
Pa rt 2 - Palpation , Part 3-Percussion. Pa rt 4 - Auscultation, Part 5 Abdominal Pain and Part 6 - D iffe rential D iagnosis of Abdominal
Disorders. Write to : The Medical Departm ent , A H . Robins Company,
1407 Cummings Drive. Richmond , Virginia 23220 .
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The A. H . Robins G .I. Series consists of six booklets, designed to provide a quick , yet comprehen- \ · 1
sive review of basic p rocedures and practices in
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physical examination as performed in the office o r ~' · ~
at bedside . If yo u have teac hing responsibilities
' ......
limited qua ntities are available• Part 1 - Inspection ,
Part 2 - Palpation, Part 3 - Perc ussion , Part 4 -A usc ultation, Part 5 Abdom ina l Pain and Part 6- Differential Diag nosis o f Abdominal
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Normally palpable organs:
the edge of the li'ier descending ,
on inspiration , below the costal
margin (A); the lower pole of the
right kidney (8); the abdominal
aorta (C); the descending colon
and the sigmoid (0) ; the ascending colon (E); and occasionally
the bladder (though rising of
this organ beyond the pubis
does not necessarily indicate
disease).
Impossible to outline, unless
diseased, distended or enlarged :
the gallbladder, panc reas,
stomach , small intestine, transverse colon and spleen.
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